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Vascular Endothelial Growth Inhibitor (VEGI) is an endothelial cell autocrine factor and a 
member of the tumor necrosis family of ligands.  VEGI is able to specifically inhibit endothelial 
cell growth and is an efficient inhibitor of angiogenesis. The molecular mechanisms of VEGI 
activity on endothelial cells remain undefined. Here we focused on two important steps in the 
signal transduction of VEGI. We first determined a role of NF-κB in VEGI-induced apoptosis. 
We found that inhibition of the NF-κB pathway resulted in an increased apoptotic potential of 
VEGI. We conclude that the NF-κB pathway plays a role in suppressing the apoptotic potential 
of VEGI. We next investigated the receptor responsible for VEGI-induced endothelial cell 
apoptosis. DR3 is a receptor for VEGI and thus we first focused on confirming if DR3 is the 
receptor responsible for VEGI-mediated endothelial cell death.  We determined VEGI had 
diminished apoptotic activity in endothelial cells that are depleted of DR3 by siRNA. However, 
it was determined that the apoptotic stimuli, LPS and TNFα, were also unable to mediate cell 
death in DR3-depleted endothelial cells.  We conclude that DR3 is mediating an intracellular 
event that is involved in controlling the apoptotic pathway. This is a novel role of DR3 that is yet 
to be described. However, this role of DR3 interferes with our analysis of the ligand/receptor 
relationship and therefore we were unable to confirm that DR3 is the receptor responsible for 
VEGI-induced apoptosis. We also provide preliminary evidence that VEGI is utilizing an 
   v 
unknown receptor to mediate NF-κB activation.  We therefore provide several mechanisms to 
control VEGI-mediated endothelial cell death, one being the activation of NF-κB to suppress the 
apoptotic potential of VEGI and the needed presence of DR3 for VEGI to initiate apoptosis, a 
role that is possibly independent of ligand binding.  
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1.0  INTRODUCTION 
The realization that tumor growth is dependent on angiogenesis has significantly changed the 
approach to cancer therapy. Understanding the molecular and cellular mechanisms that mediate 
angiogenesis is an area of intensive biomedical research. An extensive effort in drug 
development is now underway dedicated towards developing inhibitors of endothelial cell 
growth. Due to the natural and inherent capabilities of endogenous angiogenesis inhibitors to 
modulate endothelial cell growth there is focus to use these molecules as anti-angiogenic drugs.  
 
1.1  ENDOTHELIUM 
The endothelium is a type of simple squamous epithelium consisting of the largest organ in the 
body with an aggregated mass of ~1kg and a large surface area ~7000 m2 (Pries et al., 2000). The 
endothelium consists of approximately 6x1013 polarized endothelial cells, with a luminal side in 
contact with the plasma and the abluminal side bathed by the interstitial fluid (Gimbrone, 1986).  
The endothelium is distributed throughout the body and therefore in a favorable position to 
mediate multiple functions and maintain homeostasis throughout the body. Once thought as a 
simple barrier between blood and tissue, the endothelium is now known to play an active role in 
vital functions including the maintaining the equilibrium of body fluids, the regulation of 
vascular tone, coagulation, and activation of inflammation (Gimbrone, 1986). The majority of 
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mature endothelial cells in the endothelium are mainly in a quiescent state with a cell-turnover 
marked in years and (Tobelem, 1990).  
 
1.2  ANGIOGENESIS AND TUMOR PROGRESSION  
Angiogenesis refers to the process of the formation of new capillary sprouts from pre-existing 
capillary vessels. Angiogenesis occurs during normal physiological processes such as embryonic 
development and the ovarian cycle. Angiogenesis is also associated with pathological conditions 
such as tumor growth, macular degeneration, and rheumatoid arthritis (Klagsbrun and Moses, 
1999).    
 The angiogenic process is well studied and the major steps in the formation of new 
vasculature have been summarized (Bergers and Benjamin, 2003).   The process begins with 
vasodilation and the increased permeability of pre-existing capillaries. The surrounding pericytes 
of the capillaries then loosen and become detached from the capillaries. The endothelial cell 
basement membrane is degraded by matrix metalloproteinase allowing for endothelial cell 
migration towards a chemotactic signal.   Endothelial cells are able to interact with the 
extracellular matrix during the migration through interactions of the cell-surface intergrins such 
as αvβ3 and αvβ5.  Endothelial cells then proliferate to form a migration column differentiate, 
change shape and adhere to form the lumen. The newly formed vessel then deposits a new 
basement membrane and pericytes are then recruited to stabilize the vessel wall.  
 A correlation between angiogenesis and tumor growth was first reported in the early 1900s. 
In 1904, Ribbert postulated that tumors establish a superior vascular supply to that of other 
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tissues (Ribbert, 1904). In 1908, Bowen raised the notion the obliteration of the vascular supply 
as a potential site for therapy (Bowen 1908).  However, the medical value of angiogenesis was 
not fully appreciated until 1971 when Judah Folkman hypothesized that the growth of a primary 
tumor was angiogenesis-dependent and proposed the use of anti-angiogenic therapy as an 
approach to treat human cancer (Folkman, 1971).  Over the next 30 years at least 18 anti-
angiogenic inhibitors have been placed in clinical trials for the use as cancer therapeutics 
(McCarty et al., 2003; Folkman, 2007).  The first angiogenesis inhibitor, bevacizumab, was 
approved by the Food and Drug Administration in 2004 for the treatment of metastatic colon 
cancer and later approved in 2006 for first line treatment of patients with advanced nonsquamous 
nonsmall cell lung cancer. 
  The progression of cancer is a multistep process as shown in figure 1, in which a growth of 
normal and neoplastic tumor mass must activate oncogenes for continued growth signaling and 
inactivate tumor suppressors to become irresponsive to growth inhibition and apoptotic signaling 
(Davis, 2007). One of the crucial steps involved in the conversion of cancer to a deadly disease is 
the ability of the tumor to obtain and manipulate a vasculature for its growth and dissemination 
of cells to secondary sites (Folkman, 1990).  
  4 
 
Figure 1.  The progression of a tumor to a malignant phenotype is angiogenesis-dependent. 
Genetic abnormalities lead to the growth of a microscopic tumor to a ~1mm mass where it 
remains as a dormant tumor. The balance of pro- and anti-angiogenic factors are in an 
equilibrium resulting in a stable disease.  Tumor progression at this stage is marked by the 
ability of the tumor to secrete pro-angiogenic factors shifting the balance of factors towards 
an angiogenic state thereby resulting in the recruitment of blood vessels from the 
surrounding stroma. The increased vasculature of the tumor provides increased nutrients 
allowing for the growth of the tumor to a macroscopic mass. The new bloods vessels allow 
for metastasis eventually leading to the death of the host.  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1.3  REGULATORS OF THE ANGIOGENIC BALANCE 
 
Under normal conditions the endothelium is thought to be in a state controlled by a balance 
between pro- and anti- angiogenic factors.  The process of converting the quiescent endothelium 
into a state of angiogenesis is known as the “angiogenic switch”, in which there is a shift in the 
balance towards the pro-angiogenic factors. Since the angiogenic switch is necessary for the 
onset of tumor progression and several other pathological conditions there is extensive research 
directed towards understanding the factors involved in the switch.  A prominent pro-angiogenic 
factor is vascular endothelial growth factor (VEGF). VEGF is a potent endothelial cell mitogen 
and key regulator of both physiological and pathological angiogenesis.  VEGF (VEGF-A) 
belongs to a family of growth factors consisting of placenta growth factor, VEGF-B, VEGF-C 
and VEGF-D (Ferrara, 2002).  In addition to its proliferative activities VEGF is a pro-survival 
factor able to induce a variety of anti-apoptotic proteins (Alon et al., 1995). VEGF is potent 
permeability factor able to induce vascular leakage, which is important in inflammation (Kirk 
and Karlik, 2003). The previously mentioned anti-angiogenic drug, bevacizumab, is directed 
towards blocking the action of VEGF.  Another endothelial-specific growth factor is 
angiopoietin -1 (Ang-1) is known to be important in the stabilization and maturation of blood 
vessels by the recruitment of pericytes to the blood vessel (Sato et al., 1995). Basic fibroblast 
growth factor (bFGF) is another important factor in regulating angiogenesis and is responsible 
for mediating and maintaining endothelial cell survival (Fuks et al., 1994; O'Connor et al., 2000).   
 The endogenous anti-angiogenic factors are important in stabilizing and maintaining the 
vasculature in a quiescent state. During normal physiological angiogenesis the anti-angiogenic 
factors oppose the actions of the pro-angiogenic factors in order to bring the angiogenic process 
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to an end.   A number of endogenous inhibitors have been identified (Figure 2).  However, their 
mechanisms of action are not as understood as compared to what is known about the 
mechanisms of the pro-angiogenic factors. One of the first endothelial-cell specific inhibitors 
identified was thrombospondin-1 (TSP-1) (Good et al., 1990). TSP-1 is a large multifunctional 
ECM glycoprotein that mediates its activity by binding to CD36, a class B scavenger receptor, 
and triggering apoptosis (Jimenez et al., 2000). TSP-1 is an effective inhibitor of tumor growth 
and metastasis (Streit et al., 1999; Rodriguez-Manzaneque et al., 2001). 
 
 
Figure 2. Endogenous inhibitors of vascular growth. 
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Two other well-known endogenous inhibitors are angiostatin and endostatin.  Angiostatin, is a 
38-kD to 45 kd cryptic fragment of plasminogen containing kringles-1 and -4 to kringle-1 and 3 
(Cornelius et al., 1998).  Angiostatin is able to mediate endothelial cell apoptosis (Lucas et al., 
1998) and is able to bind and block ATP-synthase on the surfaces of endothelial cells, thereby 
inhibiting proliferation (Moser et al., 1999).  Endostatin is a 20-kDa C-terminal fragment of 
collagen XVIII is a broad-spectrum anti-angiogenic effect and shown to be a potent inhibitor of 
tumor angiogenesis (Folkman, 2006; O'Reilly et al., 1997).  Endostatin inhibits endothelial cell 
migration, induce apoptosis in endothelial cell, bind to ATP on the endothelial cell surface, and 
block the actions of the metalloproteinase (Dhanabal et al., 1999; Shichiri and Hirata, 2001; 
Nyberg et al., 2003). 
 
1.4  ANGIOGENESIS-DEPENDENT DISEASES 
As mentioned above, angiogenesis is a necessary step in the progression of a tumor. It should be 
noted that angiogenic therapy might not only benefit cancer therapy but also be helpful to 
unrelated disease states angiogenesis-dependent. Autoimmune disorders, age-related macular 
degeneration and atherosclerosis are known to require angiogenesis in order for disease 
progression (Miller, 1997; Smolen and Lipsky, 2003). Anti-angiogenic therapy has been referred 
to as an “organized principle” for drug discovery (Folkman, 2007). As there are clinical 
advantages for angiogenesis inhibitors approved for one disease such as cancer, can be used for 
another disease. One such example is Ranibizumab a variant of the drug Bevacizumab that is 
successful in recovering eyesight of patients with age-related macular degeneration (Rosenfeld et 
al., 2006).  Thus, the development of anti-angiogenic drug development can benefit not only 
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cancer research but also a broader spectrum of benefits towards multiple diseases.  
 
1.5  TUMOR NECROSIS SUPERFAMILY 
The necrosis factor (TNF) family of ligands consists of 19 type II transmembrane proteins 
characterized by a conserved C-terminal domain required for receptor binding known as the TNF 
homology domain (THD) (Bodmer et al., 2002). Most members are membrane-bound proteins 
that are made into soluble ligands following proteolytic cleavage by metalloproteases of the 
ADAM (a disintegrin and metalloproteinase domain) family (Black et al., 1997). TNF ligands 
exist as trimers, with a hallmark structure of anti-parallel beta-pleated sheet sandwich in a 
standard jellyroll topology (Jones et al., 1989).   
 The TNF family of receptors consist of 29 type I transmembrane proteins with the 
exception of BCMA, TAC1, BAFFR, and XEDAR, which are type III transmembrane proteins. 
The extracellular portions are characterized by the presence of cysteine-rich domains which are 
pseudo-repeats typically containing six cysteine residues engaged in the formation of three 
disulfide bonds (Bodmer et al., 2002).  Four members of the TNF receptor family are produced 
as soluble proteins known as the decoy receptors; DCR1, DCR2, DCR3 and osteoprotegrin, that 
are generally thought of as negative regulators of cell signaling. TNF receptors are classified into 
two groups depending on whether or not the receptor contains an intracellular domain, known as 
the death domain. The death domains are responsible for activating the caspase pathway and 
deletion of this domain abolishes ligand-induced apoptosis (Itoh and Nagata, 1993). Death-
domain containing TNF receptors are referred to the death receptors consisting of TNFR1, 
CD95, DR3, DR4, DR5, DR6, EDAR, and NFGR.  
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 It was initially thought that TNF ligands are able to induce receptor trimerizaiton leading to 
their activation. However, studies with the prototypic death receptor, TNFR1, reveal that TNFR1 
exists as a pre-formed trimer at the cell-membrane (Chan et al., 2000). Formation of the pre-
formed trimer requires an extracellular domain called the pre-ligand domain. Thus, TNFα does 
not mediate aggregation of TNFR but rather induces a conformational change in the pre-formed 
receptor allowing for the recruitment of downstream adaptors.  Homologous pre-ligand domains 
are also found in other TNF receptors such as DR3 and DR5 and thus is predicted other TNF 
receptors exist as pre-formed trimers on the cell-surface (Chan et al., 2000).    
 TNF ligands upon binding to their cognate receptor can activate several signaling pathways 
to mediate their cellular responses including NF-κB, JUN N-terminal kinase (JNK), p42/p44 
mitogen-activated protein kinase (MAPK), and p38 MAPK.  Activation of these pathways can 
initiate a host of biological functions involved in immune surveillance, haematopoiesis, 
protection against microbial infection, innate immunity, and tumor regression. Several of TNF 
ligands can expand their biological activities by binding to multiple TNF receptors (Figure 3) 
(Ashkenazi, 2002). Signaling activated by TNFα serves as a paradigm for most of the TNF 
superfamily members.  In particular, studies with TNFα binding to TNFR1 are used to map out 
the proteins involved in the signaling cascade common to the death receptors. TNFα binding to 
TNFR1 first leads to the recruitment of the adaptor protein, TNFR-associated death domain 
protein (TRADD) and binds to the death domain of TNFR1 (Baud and Karin, 2001). TRADD 
serves as platform for further recruit of other adaptor proteins and it this point the adaptor 
proteins exhibit two distinct signaling arms of TNFR1.  One arm involves activation of the pro-
survival and inflammation cascades and the second arm consists of activating the caspase 
pathway leading to cell death (Hsu et al., 1996). One of the essential adaptor proteins in the pro-
  10 
survival signaling arm of TNFR signaling is TNF-receptor-associated factor 2 (TRAF2) 
belonging to the TRAF family of proteins. TRAF2 compromises a highly conserved C-terminal 
TRAF domain (C-domain) and a more variable N-terminal domain that contains a ring finger and 
several ZN fingers (Arch et al., 1998). TRAF2 and other TRAF family members are responsible 
for the activation of IKK, JNK, and p38 (Liu et al., 1996). The second signaling arm involves the 
recruitment of the Fas-associated death domain protein (FADD). Upon recruitment of FADD to 
Figure 3. Members of the TNF family of ligands and their cognate receptors. Arrows 
indicate receptor binding. The ligands for several receptors are yet to be identified, 
indicated by question marks. Diamonds indicate cysteine-rich domains. Red bars indicate 
death domain capable of inducing apoptosis.  
 
the receptor complex it can interact and activate the initiator caspases, caspase-8/10 (Muzio et 
al., 1996). The receptor-interacting serine/thereonine kinase (RIP) family of adaptor proteins are 
known to be involved in both the pro-survival and pro-apoptotic signaling arms of TNFR. RIP 
contains a C-terminal death domain and N-terminal serine/thereonine protein kinase domain 
(Stanger et al., 1995). The RIP1 family member is a key effector in the activation of NF-κB (Liu 
et al., 1996) and the RIP2 and RIP3 family members are involved in both NF-κB activation and 
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apoptosis (Yu et al., 1999; McCarthy et al., 1998). These adaptor proteins create a modularity of 
TNF receptors allowing for the flexibility of mediating multiple biological functions.  
1.5.1  TNFSF15; Vascular endothelial growth inhibitor (VEGI); TL1A 
VEGI is an endogenous inhibitor of endothelial cell growth (Figure 2) and a member of the TNF 
family of ligands (Figure 3). The crystal structure of VEGI has been determined (Jin et al., 
2007a; Jin et al., 2007b).  It was determined that there are three VEGI monomers in the 
asymmetric unit and they are related by a 3-fold non-crystallographic symmetry.  These 
monomers form a trimer and assume a jellyroll β-sandwich typical of other members of the TNF 
family of ligands.  A multiple structure alignment between VEGI and other members of the TNF 
reveals that most strands have a very similar length and their overall structures superimpose with 
one another revealing that there is a greater resemblance between VEGI and the TNF ligands as 
would be predicted from the sequence homology. A loop between strands C and D in VEGI is 
the longest among the TNF ligand members, while the AA’ loop, part of which is disordered, in 
VEGI is the second longest after that in TRAIL. Similar loops in TNFβ/LTα are known to 
participate in receptor binding.  
  VEGI mRNA expression is detected predominantly in endothelial cells and VEGI gene 
transcripts are found in many human tissues, including placenta, lung, kidney, skeletal muscle, 
pancreas, spleen, prostrate, small intestine and colon (Tan et al., 1997; Zhai et al., 1999a). Figure 
4 shows the vascular localization of VEGI found in placenta and bladder tissue.  There are three 
isoforms of VEGI designated, VEGI-251, VEGI-192, and VEGI-174. The expression profiles of 
VEGI-251 and VEGI-174 have been described (Chew et al., 2002).  The 7.5 kb transcript 
encoding VEGI-251 is expressed at high levels in the placenta, kidney, lung and liver, whereas 
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the 2 kb transcript corresponding to VEGI-174 is detected in liver, kidney, skeletal muscle and 
heart. The VEGI-174 mRNA is more abundant in heart, skeletal muscle, pancreas, adrenal gland, 
and liver, while VEGI-251 is more abundant in fetal kidney and fetal lung. Overlapping of the 
two transcripts is detected in prostate, salivary gland and placenta. When examined in cultured 
cells by using RNAse protection assay, all three isoforms are found in human endothelial cells, 
including coronary artery endothelial (HCAE), human umbilical-vein endothelial cells 
(HUVEC), and human microvascular endothelial (HMVE) cells. Although the isoforms are 
present simultaneously, VEGI-251 is the most abundant. These expression patterns suggest the 
possibility of tissue- or developmentally specific functions for the variants of VEGI.  
  13 
  
Figure 4. Localization of VEGI in the vasculature. Top, the microvessel-rich placenta 
shows a similar pattern of both endothelial-cell marker CD31 and VEGI. Lower panels,  
Low and High magnification of normal human bladder tissue. VEGI expression in blood 
vessels of the bladder is found in the endothelial lining of arteries (A) and veins (V). Note 
VEGI expression is found throughout the arterial wall.  
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The anti-angiogenesis activity of VEGI was assessed in two angiogenesis models. In an in vitro 
angiogenesis model, recombinant VEGI-174 was used to treat ABAE cells grown on a layer of 
collagen gel (Zhai et al., 1999b).  When stimulated with fibroblast growth factor-2 (FGF2), 
untreated ABAE cells formed a network of capillary-like tubes in the gel. Addition of the VEGI-
174 preparation completely inhibited the capillary formation but did not cause cell death. In 
another experiment, human vascular endothelial cell line transfected with a VEGI-expressing 
plasmid exhibited a decreased ability to form microtubules in Matrigel, a reconstituted basement 
membrane (Conway et al., 2007). When evaluated in the chick embryo chorioallantoic 
membrane (CAM) model, recombinant VEGI-174 inhibited about 50% of the neovascularization 
induced by either FGF or VEGF (Zhai et al., 1999b). These results suggest that VEGI can inhibit 
capillary formation regardless of the types of angiogenic stimuli. In a different approach, an 
adenovirus expressing a fusion protein consisting of endostatin and the C-terminal 151 residues 
of TNFSF15, termed AdhENDO-VEGI151, were shown to be able to prevent angiogenesis in 
both the CAM model and a rabbit corneal neovascularization model (Pan et al., 2004). 
 VEGI is an important factor in vascular biology. However, similar to other members of the 
TNF family of ligands VEGI can elicit a number of activities on immune cells. VEGI increases 
the responsiveness of T cells to IL-2, although VEGI alone does not induce proliferation of T 
cells (Migone et al., 2002). Pre-treatment with VEGI enhances T cell proliferation in response to 
IL-2, increases IL-2Rα and β expression, and induces secretion of interferon-γ (IFN-γ) and 
granulocyte-macrophage colony stimulating factor (GM-CSF). Additionally, IL-2 receptor IL-
2Rα (CD25) and IL-2Rβ (CD122) expression increases in VEGI treated cells. Recombinant 
VEGI protein was shown to stimulate dendritic cells (DCs) maturation (Tian et al., 2007) VEGI-
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stimulated DCs are able to facilitate the proliferation and differentiation of CD4+ naive T cells in 
co-cultures. VEGI was also shown to be strongly up-regulated in human monocytes and dendritic 
cells when the FcγR signaling pathway is activated (Prehn et al., 2007).  
 VEGI is a ligand for two TNF receptors: DR3 and DcR3 (Migone et al., 2002). Using a 
293F cell line stably expressing full-length VEGI on the cell surface, a Fc-fusion form of the 
extracellular domain of TNFR family members including TNFR1, Fas, HveA, DR3, DR4, DR5, 
DR6, DcR1, DcR2, DcR3, OPG, RANK, AITR, TACI, CD40, and OX40 were evaluated for 
binding. The results show that only DR3 or DcR3 can bind to the VEGI protein on the 293F 
cells. In another experiment, a FLAG-tagged soluble form of VEGI was applied to cells 
transiently transfected with various members of the TNFR family, including TNFR2, LT R, 4-
1BB, CD27, CD30, BCMA, DR3, DR4, DR5, DR6, DcR1, DcR2, RANK, HveA, and AITR. 
The tagged VEGI was found to bind only to DR3-overexpressing cells. In addition, direct 
interaction between VEGI and DR3 was detected by co-immunoprecipitation. Another 
independent group also confirmed the binding of VEGI to DR3 and DcR3 in a flow cytometry- 
based assay (Bossen et al., 2006). 
1.5.2     TNFRSF25; Death Receptor 3 (DR3) 
DR3 is a death-domain containing receptor having 4 cysteine-rich domains in its extracellular 
region.  Several groups indentified DR3 independently (Marsters et al., 1996; Bodmer et al., 
1997; Kitson et al., 1996). Several of the approaches utilized EST database searching for 
homologous TNFR domains.  One approach used a two-hybrid system (Kitson et al., 1996). In 
attempt to find interacting proteins with TNFR1, Kitson et al cloned the death domain of TNFR1 
and constructed GAL4 fusion protein using the fusion protein in a HeLa cell two-hybrid library   
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Seven clones were indentified that interacted specifically with TNFR1 death domain, 6 of which 
encoded cytoplasmic regions of TNFR1. The seventh clone was indentified to be a new 
complementary DNA, later to be named DR3. The expression of DR3 is enriched in lymphocyte-
rich tissues such as peripheral blood lymphocytes, thymus, colon, intestine, and spleen (Bodmer 
et al., 1997). DR3-/- mice were determined develop normally with no obvious abnormalities 
(Wang et al., 2001). It was revealed that DR3-/- mice are impaired in the negative selection of 
anti-CD3-induced apoptosis in the thymus suggesting a role of DR3 in the removal of self-
reactive T cells in the thymus. 
 Ectopic overexpression of DR3 activates NF-κB and apoptosis (Kitson et al., 1996; 
Marsters et al., 1996).  Following the identification of VEGI as a ligand for DR3 it was 
determined that VEGI-induced activation of DR3 recruited TRADD, TRAF2, and RIP and 
activated the NF-κB, ERK, JNK, and p38 mitogen-activated protein kinase pathways in human 
erythroleukemic TF-1 cells (Migone et al., 2002).  Alternative splicing of DR3 results in at least 
11 isoforms (Screaton et al., 1997; Warzocha et al., 1998). Eight of the isoforms lack 
transmembrane domains and thus are predicted to be secreted soluble variants of the receptor. 
Most isoforms contain premature stop codons and are predicted to be targeted for degradation by 
the mRNA surveillance mechanism, nonsense mediated RNA decay (Hillman et al., 2004).  
Alternative splicing of DR3 in peripheral blood lymphocytes (PBLs) results “on” and “off” state 
in state of DR3 (Screaton et al., 1997).  In non-activated PBLs the DR3 isoforms mainly exist in 
the soluble state and unable to mediate cell signaling.  Following the activation of PBLs, the 
DR3 isoforms undergo an isoform switch from the soluble to the membrane-bound isoform, the 
functional variant needed for cell signaling.  
 DR3 interacts with two endothelial-specific gene products. One, as previously mentioned, 
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is the TNF ligand VEGI. The other is the endothelial cell-surface protein, E-selectin (Gout et al., 
2006).  Gout et al studied the interactions of DR3 expressed on colon carcinoma cells HT29 and 
E-selectin expressed on human umbilical vein endothelial cells.  Using siRNA to deplete DR3 or 
its neutralization by an antibody on HT29 cells impaired the adhesion, transendothelial cell 
migration, and activation of p38 and ERK by E-selectin. Thus, DR3 serves as a counter-receptor 
for E-selectin and may be involved in the metastatic process in which cancer cells must bind to 
the endothelium in order to extravasate to the secondary site.  Also, the reverse signaling of E-
selectin activation of DR3 conferred pro-survival signaling in the colon cancer cells thus 
fortifying the survival of cancer cells.      
1.6   THE NF-κB PATHWAY 
The Rel/NF-κB family is consists of the five members: c-REL, RelA, RelB, p1025/NF-κB1 and 
p100/NF-κB2.  The Rel family members are able to form homo- or hetero- dimers with other 
family members and each member posses a 300 amino acid N-terminal domain, known as the 
Rel homology domain (RHD). The REL domain is responsible for dimerization, nuclear 
translocation and DNA binding. This family can be divided into two groups classified by 
whether the member is synthesized as a mature protein or produced as a pre-cursor protein that 
needs to be proteolytically cleaved in order to be active.  The members Rel A (p65), c-Rel and 
RelB, are produced as mature products and do not require proteolytic processing.  The second 
group is encoded by NF-κB1 (p50/105) and NF-κB2 (p52/100) genes are first produced as large 
precursors, p105 and p100 then proteolytically cleaved to form the mature p50 and p52 NF-κB 
proteins.   
 Shuttling to the nucleus and the cytoplasm modulates the activity of the NF-κB family 
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members. The IκB family of proteins are responsible for inhibiting NF-κB/Rel activity by 
binding and retaining the transcription factors in the cytoplasm. There are seven known 
mammalian IκB members, IκBα, IκBβ, IκBε, IκBγ, BCL-3 and the precursors REL proteins 
p100 and p105 (Ghosh et al., 1998). The IκBs proteins are able to sequester NF-κB by the 
presence of multiple ankyrin repeat, which are protein-protein interaction domains that interact 
with NF-κB via the RHD.  The dimerization domain of the NF-κB dimers is the primary region 
of interaction with IκBs and differences in the interactions mounted by IκBα and IκBβ may play 
a role in regulating NF-κB activity (Ghosh and Karin, 2002).  
 Figure 5 shows the essential steps in the activation of the NF-κB leading to gene 
expression. Activation of the canonical NF-κB begins with a ligand stimulation and activation of 
the IKK complex. The mechanism that leads to the active IKK complex by TNF signaling is still 
unclear. IKK is a large complex (700-900 kDA) composed of IKKα (IKK1), IKKβ (IKK2) the 
catalytic subunits, and IKKγ (NEMO), the regulatory subunit (Rothwarf and Karin, 1999).  The 
IKK complex activates NF-κB by phophorylating the inhibitor IκB family of proteins. IKKα and 
IKKβ both target two serines in the N-terminal regulatory domain of IκB proteins, with IKKβ 
being the more potent kinase (Zandi et al., 1997). The phoshporlyation of the IκBs tags the 
proteins for polyubiquitination by the ligase, beta-TrCP, belonging to the SCF family (Ben-
Neriah, 2002). Following ubiquitination of the IκBs they are degraded thereby freeing NF-κB 
and allowing for nuclear translocation where binds to DNA, and activates transcription.  DNA 
binding consists of NF-κB dimer making a complex with each contact on one half of the DNA 
binding site, slight variations in the 10 base pair consensus sequence 5’GGGGYNNCCY3’ 
confer preference to selected Rel members (Kunsch et al., 1992) 
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Figure 5. The canonical NF-κB pathway.  NF-κB is sequestered in the cytoplasm by the 
inhibitor IκBα . Upon stimulation of the cell this leads to activation of the IKK complex.  
The IKK complex is able to phosphorylate IκB marking it for proteosome-mediated 
degradation. NF-κB is freed and able to translocate to the nucleus where it is able to 
initiate transcription.  (See text for details) 
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1.7  THE CASPASE PATHWAY 
Apoptosis or programmed cell death sometimes referred to as cell suicide is a tightly regulated 
process that removes unnecessary cells from an organism and plays an important role in tissue 
homeostasis.  Apoptosis is distinguishable from necrosis, as it does not lead to inflammation and 
neighboring cells are unaffected.  
 Caspases are the central components of the apoptotic response. The involvement of these 
enzymes in apoptosis was first realized in studies with the characterization of nematode worm 
Caenorhabditis elegans gene, ced-3 (cell death abnormality-3) and determined to closely 
resemble the mammalian caspase-1 (Yuan et al., 1993).  Caspases are a conserved family of 
proteins and to date 14 mammalian caspase have been indentified with 11 being in humans (Shi, 
2002).  Caspases are produced as zymogens and during the initiation of the apoptotic process 
must undergo proteolytic processing in order to activate the next sequence of caspases. Caspases 
can be divided into two groups: the initiator caspases (-2, -8, -9 and -10) or the effector caspases 
(-3, -6, and -7), the initiator caspase able to auto-activate and activate the effector caspases.  The 
initiator caspases cleave specific aspartate residues found in the effector caspases resulting in the 
formation of two subunits the large (~p20) and small (~p10) subunits (Riedl and Shi, 2004). The 
caspase cascade is tightly regulated and often requires the assembly of a multi-component 
complex during apoptosis (Adams and Cory, 2002).  
 Depending on the origin of the apoptotic stimuli whether from inside the cell or from 
extracellular stimuli the pathways known as the intrinsic pathway or the extrinsic pathway, 
respectively.  The intrinsic pathway is mediated by the mitochondria and can be triggered by 
such events such as DNA damage (Wang, 2001). Activation of the intrinsic pathway results in 
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the release of several proteins from the intermembrane space of the mitochondria into the 
cytoplasm. One important factor that is released is cytochrome c, which is responsible for 
activating the protein APAF1 leading to the formation of the apoptotsome and activates caspase-
9 and the remaining caspase cascade (Li et al., 1997; Zou et al., 1999). The extrinsic pathway is 
initiated by the binding of extracellular death ligands, which leads to formation of the death 
inducing signaling complex and activation of caspase-8 (Rath and Aggarwal, 1999). Caspase-8 is 
activated through an induced proximity mechanism. Fadd and caspase-8 are necessary for 
TNFR1-, FAS-, and DR3- induced apoptosis (Yeh et al., 1998;Varfolomeev et al., 1998).  
 Caspase activation by either the intrinsic or extrinsic pathway will eventually lead to the 
degradation of cytoskeletal and nuclear proteins critical for maintenance of cell structure and 
cleavage of other enzymes necessary for cell survival and DNA fragmentation (Enari et al., 
1998; Thornberry and Lazebnik, 1998). 
1.8  SCOPE OF THIS DISSERTATION 
Vascular endogenous growth inhibitor is an endogenous inhibitor of angiogenesis that belongs to 
the TNF superfamily of ligands. To date the molecular mechanisms underlying the regulation of 
VEGI signaling are not clearly described. We investigated two important mechanisms of VEGI 
action on endothelial cells while trying to determine the therapeutic potential of this unique 
cytokine.  
 Our first investigation was to determine the role of NF-κB in VEGI-mediated endothelial 
cell death.  NF-κB is an anti-apoptotic factor known to be activated by VEGI.  Since we observe 
cell death under normal signaling of VEGI we wanted to establish if in fact NF-κB is utilized as 
an anti-apoptotic factor in endothelial cells. We used either siRNA as well as NF-κB inhibitors in 
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order to prevent VEGI-induced NF-κB activation. We determined that inhibition of the NF-κB 
pathway resulted in an increased apoptotic potential of VEGI, suggesting that NF-κB suppresses 
VEGI-induced apoptosis.  This study suggests a new approach to use VEGI with NF-κB 
inhibitors in order to improve its anti-angiogenic potential.   
In addition we sought to determine the essential receptor required for VEGI in regulating 
endothelial cell death. We investigated if the known receptor for VEGI in TF-1 cells, DR3, is the 
major receptor responsible for mediating VEGI-induced apoptosis in endothelial cells. We were 
unable to clarify if DR3 is the major receptor because the removal of DR3 had a unique impact 
on the cells. However, we determined that DR3 is involved in regulating the apoptotic pathway 
of several apoptotic stimuli such as LPS and TNFα. Furthermore, this investigation also gives 
preliminary evidence of a novel receptor for VEGI in endothelial cells. 
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2.1  ABSTRACT 
Vascular endothelial growth inhibitor (VEGI) is a member of the tumor necrosis factor 
superfamily and endothelial-cell autocrine factor that induces apoptosis in proliferating 
endothelial cells. We investigated the relationship between VEGI-induced NF-κB activation and 
apoptosis in endothelial cells. NF-κB or its activator IKK2 was depleted from adult bovine aortic 
endothelial cells using short interfering RNA (siRNA). Depletion of these molecules prevented 
VEGI-induced NF-κB activation, evidenced from a reduced extent of NF-κB nuclear 
translocation and diminished expression of NF-κB-target genes such as interlueukins-6 and -1β. 
The siRNA-treated cells when exposed to recombinant VEGI exhibited markedly decreased cell 
viability and significantly increased apoptosis. Alternatively, inhibition of NF-κB activation with 
specific inhibitors, curcumin and BMS-345541, gave similar results. These findings suggest that 
VEGI-induced apoptosis in endothelial cells is accompanied by a concomitant activation of the 
pro-survival NF-κB pathway, which modulates the extent of cell death. VEGI is a potential anti-
angiogenic therapeutic agent. Our findings indicate that sensitization of endothelial cells to 
VEGI-induced apoptosis by inhibiting the NF-κB pathway could be a useful strategy in anti-
angiogenic and anti-cancer treatment.   
 
2.2  INTRODUCTION 
Vascular endothelial growth inhibitor (VEGI; also known as TL1A) belongs to the TNF 
superfamily of ligands (TNFSF15)  (Tan et al., 1997).   VEGI is expressed predominately by 
vascular endothelial cells and inhibits endothelial cell growth by an autocrine mechanism (Zhai 
et al., 1999a; Kim and Zhang, 2005; Yang et al., 2004).   Uniquely, the inhibition effect of VEGI 
is selective towards vascular endothelial cells (Zhai et al., 1999a; Hou et al., 2005).  VEGI 
  25 
inhibits endothelial cell growth in two ways: it induces apoptosis in proliferating cells or 
enforces a growth arrest if the cells are in G0 or early G1 of the growth cycle (Yu et al., 2001).   
In murine tumor models recombinant VEGI is an effective inhibitor of neovascularization and 
tumor growth (Zhai et al., 1999a; Zhai et al., 1999b; Hou et al., 2005).   The constitutive 
expression of VEGI in the vasculature and the modulation of endothelial cell growth suggest a 
role of this cytokine in the maintenance of vascular homeostasis. 
 The ligands of the TNF family are known to typically activate the NF-κB transcription 
factor. (Gaur and Aggarwal, 2003)   NF-κB proteins are dimeric DNA binding proteins 
consisting of members of the Rel/NF-κB family of transcription factors. The predominant NF-κB 
complex is a heterodimer consisting of the p50 and p65 family members. (Baeuerle and 
Baltimore, 1989)    In resting cells the NF-κB complex is sequestered in the cytoplasm by the 
inhibitor IκBα, which masks the nuclear localization signal of NF-κB.  Ligand stimulation leads 
to activation of the IKK complex consisting of IKK1, IKK2, and IKKγ subunits. Upon 
activation, the IKK complex phosphorylates IκBα, leading to poly-ubiquitination and subsequent 
proteosome-mediated degradation. Degradation of IκBα thereby releases NF-κB, allowing the 
transcription factor to translocate to the nucleus and bind to specific DNA sequences to regulate 
expression of target genes.  
  VEGI interacts with the death receptor 3 (DR3), and determined to be a ligand for DR3 in 
human T cells (Migone et al., 2002). The death receptors are a subset of the TNF receptor family 
defined by the presence of an intracellular death domain in their primary structures capable of 
activating the caspase pathway leading to apoptosis (Baker and Reddy, 1998). VEGI treatment 
does not result in apoptosis of T cells, however activation of NF-κB is known to be responsible 
for the ability of cells to resist apoptosis by up-regulating the anti-apoptotic factor c-IAP2 (Wen 
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et al., 2003).  Interestingly, unlike T cells, endothelial cells undergo apoptosis when treated with 
VEGI. The role of VEGI-induced NF-κB activation in endothelial cells remains undefined.  
Here, we report that the prevention of NF-κB activation by either silencing key components of 
the NF-κB pathway with siRNA or using small-molecule inhibitors sensitizes endothelial cells to 
VEGI-induced apoptosis. Our findings suggest that VEGI activation of NF-κB modulates the 
extent of VEGI-induced apoptosis in endothelial cells. The use of NF-κB inhibitors to improve 
the efficacy of VEGI could be a potential strategy for anti-angiogenic and anti-cancer therapy 
 
2.3  MATERIALS AND METHODS 
2.3.1  Cells and reagents 
Adult bovine aortic endothelial (ABAE) cells were purchased from Lonza (Walkersville, MD). 
NF-κB p65 (F-6) monoclonal mouse antibody was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). IKK2 (L570) polyclonal rabbit antibody was purchased from Cell Signaling 
Technology (Danvers, MA). Curcumin was purchased from Sigma-Aldrich (St. Louis, MO). 
BMS-345541 was purchased from Calbiochem (San Diego, CA). VEGI was produced from 
E.coli as previously described (Hou et al., 2005).   One unit of VEGI activity is defined as the 
IC50 value (100-500 ng/ml) of the VEGI preparation (Tian et al., 2007).    
2.3.2  siRNA transfection 
 Custom designed siRNA duplexes were synthesized by Sigma-Proligo (St. Louis, MO). siRNA 
sequences were designed against the bovine NF-κB p65 and IKK2 mRNA: 5'-GGACGTACGAG 
ACCTTCAA-3' (p65), and 5'-AGAAAGTGCGAGTGATTTA-3' (IKK2). A scrambled siRNA 
control was purchased from Ambion (Austin, TX). Transfection was carried out with RNAiMax 
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(Invitrogen, Carlsbad, CA) and opti-MEM reduced serum medium according to manufacturer’s 
instructions overnight at 37 ºC , 5% CO2. The cells were then rinsed and maintained in normal 
growth media for 48 hours before being exposed to VEGI. 
  2.3.3   Viability assay 
 ABAE cells were seeded in black 96-well well plates. Following the treatments, the cells were 
washed once with PBS.  Calcein-AM (Invitrogen Carlsbad, CA) 1 µg/ml in PBS was then added 
to the cells and incubated for 30 minutes at room temperature. The cells were washed with PBS 
and fluorescent intensity, 485nm excitation: 520 nm emission was measured on a Tecan Safire 
fluorescence plate reader (Tecan, San Jose, CA) 
2.3.4  Western blot analysis 
Cells were subjected to lysis and total protein lysate was resolved using 12% SDS-PAGE. The 
proteins were transferred onto a Hybond-ECL nitrocellulose membrane, blocked with 5% nonfat 
dried milk powder for 1 h at room temperature, and incubated overnight at 4 ºC with the primary 
antibodies.  The membrane was washed and incubated with an appropriate HRP-conjugated 
secondary antibody and developed with the ECL system (Amersham Biosciences, Pittsburgh, 
PA).  
2.3.5  Nuclear translocation assay  
Nuclear translocation of NF-κB was analyzed using an automated fluorescence imaging system.  
ABAE cells were cultured in a 96-well plate and following treatments the cells were fixed with 
4% paraformaldehyde for 10 min, then permeabilized with PBS containing 1% Triton X-100 for 
5 min. The cells were labeled with mouse anti-p65 antibody and Alexa Fluor 488 goat anti-
mouse antibody (Invitrogen). Nuclei were stained with 1 µg/ml Hoechst 33342. Cellomics 
ArrayScan VTI HCS Reader was used to analyze the cells as previously described. (Vakkila et 
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al., 2004)   Briefly, the system scans multiple fields in a well to acquire images from a 
predefined numbers of cells as determined by the Hoechst channel. The system analyzes 
fluorescent intensity (mean pixel intensity) of nuclear and cytoplasmic regions (488 nm).   
2.3.6  QRT-PCR  
Total RNA was extracted and purified from cultured cells with an RNeasy mini-kit (Qiagen, 
Valencia, CA). RT was performed using the TaqMan® One-Step RT-PCR Kit  (ABI systems, 
Foster City, CA). Expression levels of IL-6, IL-1β, and GAPDH genes were analyzed using 
SYBR® Green kit (ABI Systems) and ABI PRISM 7700 sequence detection system. Primers 
sequences were: IL-6, forward 5'-TGAGTGTGAAAGCAGCA AGGA-3', reverse 5'-TCGCCT 
GATTGAACCCAGATT-3'; IL-1β, forward 5'-CCAGCT TCTGATGAGCAACCA-3', reverse 
5'-CAGATGCGCCTG CTTCTAGG-3'; GAPDH, forward 5'-GGCGTGAACCACGAG 
AAGTAT-3', reverse 5'-CCTCCACGATGCCAAA GTG-3'. Relative expression of the marker 
genes was calculated from the delta-Ct (threshold cycle) of the targeted gene normalized to the 
delta-Ct of GAPDH. 
2.3.7  Caspase-3 substrate assay 
 The cells were seeded in 96-well plates, and following treatments 25 µl of lysis buffer was 
added directly to the plate and incubated for 2 hours at 4 ºC with agitation. To each well was 
added 12.8 µl of Caspase buffer (312.5 mM HEPES Ph 7.5, 31.25% w/v sucrose, 0.3125% w/v 
CHAPs), 0.8 µl of DMSO, 4 µl of 100 mM DTT, 6.6 µl dH2O and 0.8 µl of 10 mM DEVD-pNA 
substrate (BioVision, Mountain View, CA). The plates were incubated overnight at 37 ºC and 
plates were read at 405 nm with a Benchmarked Plus microplate reader (Biorad, Hercules, CA).   
 
 
  29 
2.3.8  DNA fragmentation assay  
The cells were seeded in 96-well plates and following treatments the cells were subjected to an in 
situ terminal deoxynucleotidyl transferase (TUNEL) detection kit, TiterTACS (Trevigen, 
Gaithersburg, MD) according to the manufacture’s protocol.  
2.3.9 Statistical Analysis 
A one-tailed Students t test was used for comparison of two groups. Significance was defined as 
P<0.05 
 
2.4  RESULTS 
 
2.4.1  Inhibition of NF-κB activation using siRNA 
We used RNA interference technology to deplete two major components of the NF-κB pathway, 
p65 and IKK2, from ABAE cells.  siRNA targeting of either p65 or IKK2 significantly silenced 
expression of these genes such that the protein levels were marginally detectable 48 hours 
following the transfection as assessed by western blotting analysis (Figure 6A).  
 To investigate the effect of the siRNA treatments on VEGI-induced NF-κB activation we 
assayed for NF-κB p65 translocation into the nucleus, a characteristic of activated NF-κB.  
Following the transfections with the respective siRNA, ABAE cells were treated with 
recombinant VEGI for 30 minutes. The cells were fluorescently labeled for p65 and nuclear 
levels were quantified using imaging analysis (Figure 6B).  VEGI exposure to the scrambled 
siRNA control group resulted in an approximate 2-fold increase of nuclear NF-κB p65 
concentrations as compared to non-stimulated cells. The p65 siRNA sufficiently depleted the p65 
protein in the cells and, consequently, only a negligible amount of p65 could be detected in 
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nuclei following VEGI stimulation.  VEGI exposure to the IKK2-silenced cells showed 
approximately a 40% decrease in nuclear NF-κB concentrations as compared to the VEGI-
stimulated scrambled control group. 
 
 
Figure 6. RNAi depletion of NF-κB p65 and IKK2 prevents VEGI-induced NF-κB 
activation in ABAE cells. A, Western Blotting analysis of IKK2 and p65 in ABAE cells 
treated with either scrambled-, IKK2- or p65-siRNA (100 nM each, 48 h), as indicated. β-
Actin was used as a loading control. B, Nuclear levels of activated NF-κB following siRNA 
(100 nM, 48 h) and VEGI (2 units, 30 min) treatment. Cells were fluorescently labeled for 
p65 and subjected to automated fluorescent imaging analysis to determine fluorescent 
intensity of nuclear p65. Values are means ± SEM of duplicate measurements. Data are 
from a typical experiment out of three independent experiments. At least 3000 cells were 
analyzed. Asterisks, P < 0.0001. 
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We then determined the effect of siRNA treatments on the ability of VEGI to upregulate gene 
expression of the cytokines IL-6 and IL-1β, two well-known NF-κB-responsive genes. 
Following the transfections with the respective siRNA, ABAE cells were treated with VEGI for 
7 hours.  The cells were then harvested and RNA was extracted and subjected to qRT-PCR to 
determine IL-6 and IL-1β expression levels.  VEGI exposure to the scrambled control cells led to 
a 700–fold increase of IL-6 expression levels. Cells silenced of p65 or IKK2 exhibited a 90% 
and 95% decrease, respectively, in IL-6 production (Figure 7A). Additionally, VEGI exposure to 
the scrambled control cells led to a 5–fold increase of IL-1β expression levels. Cells silenced of 
p65 or IKK2 exhibited a 50% and 95% decrease, respectively, in IL-1β production (Figure 7B).  
Here, we show p65 and IKK2 siRNA treatments inhibited VEGI-stimulated NF-κB nuclear 
translocation and the ability of VEGI to upregulate expression of NF-κB-target genes therefore 
demonstrating the siRNA treatments are effective at inhibiting NF-κB activation.  
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Figure 7. RNAi depletion of NF-κB p65 and IKK2 diminishes the expression of VEGI 
regulation of NF-κB genes. A,  Quantitative RT-PCR analysis of IL-6 expression in ABAE 
cells following treatment with the indicated siRNA (100 nM, 48 h) and VEGI (2 units, 7 h). 
B, Quantitative RT-PCR analysis of IL-1β  expression in ABAE cells following treatment 
with the indicated siRNA (100 nM, 48 h) and VEGI (2 units, 7 h). Values are means ± SD of 
duplicate measurements. Data are from a typical experiment out of two independent 
experiments; **P<0.001, *P <0.05. 
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2.4.2  Inhibition of NF-κB activity coincides with increased VEGI cytotoxicity  
We then determined if NF-κB inhibition effected VEGI regulation of ABAE cell viability. 
Following the transfections with the respective siRNA, ABAE cells were exposed to various 
concentrations of VEGI for 48 hrs and then subjected to a calcein viability assay. We determined 
the half-maximum inhibition value (IC50) on the p65-silenced cells to be about 0.2 units of VEGI 
activity, a nearly 10-fold decrease from the scramble control treated cells (Figure 8A). The IC50 
value of VEGI on the IKK2-silenced cells was determined to be about 0.4 units, an approximate 
5-fold decrease from the scramble control treated cells (Figure 8B). These results show that 
endothelial cells when prevented from activating the NF-κB pathway became more sensitive to 
VEGI cytotoxicity.  
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Figure 8. Silencing of the NF-κB pathway potentiates the cytotoxicity of VEGI in ABAE 
cells. The cells were treated with the respective siRNA (100 nM, 48 h) treated with VEGI at 
the indicated concentrations (48 h), and then subjected to a calcein viability assay. A, 
Percentage of viable cells treated with either the scrambled siRNA (closed circles) or the 
p65 siRNA (open circles). B, Percentage of viable cells treated with either the scrambled 
siRNA (closed circles) or the IKK2 siRNA (open circles). Values are means ± SD of 
duplicate measurements. Data are from a typical experiment of at least two independent 
experiments. 
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Since the recombinant VEGI protein was produced in E.coli, we wanted to ensure the 
observed sensitization was not a result any present endotoxin found in the protein preparation. 
We repeated the siRNA treatments and exposed the cells to heat-denatured VEGI and found a 
complete loss of activity in the p65-silenced cells (Figure 9A) as well as the IKK2-silenced cells 
(Figure 9B).  These results demonstrate that the observed effect shown above is associated with 
the recombinant VEGI.  
 
 
Figure 9. Enhanced Cytotoxicity is specific towards VEGI. A, Percentage of viable p65-
depleted cells treated with either native VEGI (open squares) or heat-denatured VEGI 
(closed squares). D, Percentage of viable IKK2-depleted cells treated with either native 
VEGI (open squares) or heat-denatured VEGI (closed squares).  Values are means ± SD of 
duplicate measurements. Data are from a typical experiment of at least two independent 
experiments.  
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2.4.3        Inhibition of NF-κB activity enhances VEGI-induced apoptosis 
Since VEGI cytotoxicity results from induction of apoptosis, we measured caspase-3 activity to 
determine if there was an increase in the apoptotic potential of VEGI. Following the 
transfections with the respective siRNA, the cells were treated with various concentrations of 
VEGI for 7 hours and then subjected to a caspase-3 substrate (DEVD) assay (Figure 10A). VEGI 
exposure on p65-silenced cells resulted in a rapid increase of caspase-3 activity showing a 80-
fold increase at 2 units of VEGI as compared to the scrambled control treated cells. In the IKK2-
silenced cells we observed an increase of caspase-3 activity only at 2 units of VEGI.  To 
determine a dose-response effect of VEGI on the IKK-2-silenced cells we repeated the 
experiment extending the VEGI treatment to 24 hrs (Figure 10B), and observed a marked 
increase in caspase-3 activity at various VEGI concentrations in the IKK2-silenced cells as 
compared to the scrambled control treated cells.  
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Figure 10. Silencing of the NF-κB pathway facilitates VEGI-induced Caspase-3 activation. 
A, Caspase-3 activity in NF-κB pathway-silenced cells in response to VEGI. ABAE cells 
were treated with either the scrambled (Circles), p65 (Squares), or IKK2 (Triangles) 
siRNA (100 nM, 48 h), then exposed to VEGI at indicated concentrations; caspase-3 
activity was measured 7 h after VEGI treatment. B, ABAE cells were treated with the 
scrambled (Circles), or IKK2 (Triangles) siRNA (100 nM, 48 h), then exposed to VEGI at 
indicated concentrations; caspase-3 activity was measured 24 h after VEGI treatment. 
Values are means ± SD of duplicate measurements. Data are from a typical experiment out 
of two independent experiments.  
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 In addition to caspase-3 activity, we determined the degree of DNA fragmentation to 
measure apoptosis. Following the transfections with the respective siRNA, ABAE cells were 
exposed to VEGI for either 7 or 24 hours then subjected to a TUNEL assay.  At 7 hours we 
observed an approximate 3-fold increase in DNA fragmentation in the p65-silenced cells as 
compared scrambled control treated cells (Figure 11A). At 24 hours, we observed an 
approximate 2-fold increase in DNA fragmentation in the IKK2-silenced cells as compared to 
scramble control treated cells (Figure 11B).  These results demonstrate inactivation of the NF-κB 
pathway enhances the potential of VEGI to induce apoptosis in endothelial cells.  
 
Figure 11. Silencing of the NF-κB pathway facilitates VEGI-induced DNA fragmentation.  
A, Extent of DNA fragmentation (TUNEL assay) in ABAE cells treated with either the 
scrambled or p65 siRNA (100 nM, 48 h) responding to VEGI (2 units), measured at 7 h. B, 
Extent of DNA fragmentation in either the scrambled or IKK2 siRNA (100 nM, 48 h) 
treated cells responding to VEGI (2 units), measured at 24 h. Values are means ± SD of 
duplicate measurements. Data are from a typical experiment out of two independent 
experiments; **P<0.001, *P <0.05. 
  39 
2.4.4  Inhibition of NF-κB activation with small molecules 
We next used two small-molecule inhibitors, curcumin and BMS-345541, to prevent NF-κB 
activation in ABAE cells. Curcumin and BMS-345541 are able to inhibit IKK1 and IKK2 
activity. (Pan et al., 2000; Burke et al., 2003)   We first confirmed the ability of these inhibitors 
to prevent NF-κB nuclear translocation. ABAE cells were incubated with either one of the 
inhibitors for 2 hours, and then exposed to VEGI for 30 min. Analysis of fluorescent intensity of 
nuclear NF-κB p65 showed a 3-fold increase in the control cells as compared to the non-
stimulated cells. In the presence of curcumin and BMS-345541 there was about a 75% and 45% 
inhibition, respectively, in NF-κB p65 nuclear concentrations following exposure to VEGI 
(Figure 12).   
 
Figure 12. IKK inhibitors prevent VEGI-induced NF-κB nuclear translocation. A. Nuclear 
levels of activated NF-κB.  ABAE cells were treated with either curcumin (25 µM) or BMS-
345541 (1 µM) for 2 h, and then exposed to VEGI (2 units, 30 min).  Cells were 
fluorescently labeled for p65 and subjected to automated fluorescent imaging analysis to 
determine fluorescent intensity of nuclear p65.  Values are means ± SEM of two 
measurements, At least 9000 cells were analyzed; Asterisks, P < 0.0001.  
  40 
 We also determined the ability of these compounds to inhibit VEGI-induced gene 
regulation of IL-6 and IL-1β.   ABAE cells were incubated with one of the inhibitors for 2 hours, 
and then treated with VEGI for 7 hours.  QRT-PCR analysis showed the VEGI treatment led to a 
2500–fold increase of IL-6 expression levels as compared to the non-stimulated cells. In the 
presence of curcumin or BMS-345541 there was a 99% and 80%, respectively, inhibition of IL-6 
expression levels (Figure 13A). VEGI treatment led to a 40–fold increase in IL-1β expression 
levels as compared to the non-stimulated cells.  In the presence of curcumin and BMS-345541 
there was a 90% and 40%, respectively, inhibition of IL-1β expression levels (Figure 13B).   
These results confirmed the effectiveness of the inhibitors to prevent VEGI-induced NF-κB 
activation.  
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Figure 13. IKK inhibits diminished VEGI regulation of NF-kB responsive genes.  A,  
Quantitative RT-PCR analysis of IL-6 expression in ABAE cells treated with curcumin (25 
mM) or BMS-345541 (1 mM) for 2 h then exposed to VEGI (2 units, 7 h).  B,  Quantitative 
RT-PCR analysis of IL-1β  expression of ABAE cells treated with curcumin (25 mM) or 
BMS-345541 (1 mM) for 2 h then exposed to VEGI (2 units, 7 h). Values are means ± SD of 
duplicate measurements. Data are from a typical experiment out of two independent 
experiments; **P<0.001, *P <0.05.  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2.4.5  Small-molecule inhibition of NF-κB activity sensitizes ABAE cells to VEGI 
cytotoxicity 
We next determined the effect of the NF-κB pathway inhibitors on VEGI-mediated ABAE cell 
death and caspase-3 activation. We determined a 2-fold and 8-fold decrease in the VEGI IC50 
values in the presence of curcumin and BMS-345541, respectively, as compared to cells cultured 
without these molecules (Figure 14A). Furthermore, caspase-3 activation upon exposure to 
various concentrations of VEGI significantly increased when the cells were first incubated with 
either curcumin or BMS-345541 (Figure 14B). These results further demonstrate that inhibition 
of the NF-κB pathway sensitizes the cells to VEGI-induced apoptosis, thus corroborating the 
findings obtained with the siRNA.  
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Figure 14. IKK inhibitors potentiate the cytotoxicity of VEGI and apoptosis in 
ABAE cells.  A, Percentage of viable cells in the absence of an inhibitor (Circles) or treated 
with 12.25 mM curcumin (Squares) or 1 nM BMS-345541 (Triangles) for 2 h, treated with 
VEGI at indicated concentrations for 48 h, and then subjected to calcein viability assay. 
Values are means ± SD of duplicate measurements. Data are from a typical experiment out 
of two independent experiments. B, Caspase-3 activity in ABAE cells treated with IKK 
inhibitors and VEGI. ABAE cells in the absence of an inhibitor (Circles), or treated with 
12.25 µM curcumin (Squares) or 1 µM BMS-345541 (Triangles) for 2h, and then exposed 
to VEGI at indicated concentrations; the activity was measured 9 h after VEGI treatment. 
Values are means ± SD of duplicate measurements. Data are from a typical experiment out 
of two independent experiments. 
 
  44 
2.5  CONCLUSIONS 
Whether a cell lives or dies depends on a variety of stimuli that mediate either pro-survival or 
pro-apoptotic signaling pathways or at times both.  These pathways in turn modulate a network 
of proteins, and the balance of these proteins determines whether or not programmed cell death 
proceeds. (Aggarwal, 2003; Kucharczak et al., 2003)    An aberrant balance of these factors may 
lead to excessive apoptosis or ineffective induction of cell death, both conditions resulting in a 
variety of disease states. In vascular biology excessive endothelial cell apoptosis weakens 
vascular integrity and is associated with numerous conditions such as atherosclerosis (Tricot et 
al., 2000), allograft vasculopathy (Dong et al., 1996), heart failure (Rossig et al., 2000), and 
diabetic retinopathy (Mizutani et al., 1996).    Conversely ineffective apoptosis is associated with 
excessive angiogenesis as implicated in tumor growth, age-related macular degeneration, and 
arthritis (Folkman, 2007).   Thus, it is of great importance to characterize survival and apoptotic 
factors and their molecular mechanisms to further our knowledge of the endothelial homeostasis 
in normal and disease states.  
 VEGI is an endogenous inhibitor of endothelial cell growth and angiogenesis. The 
molecular mechanisms involved in this cytokine’s inhibition effect remain undefined. In this 
investigation we determined that inhibition of NF-κB activation facilitated VEGI-mediated 
endothelial cell death. NF-κB is an integral factor of TNF biology commonly known for its role 
in modulating inflammation and cytokine production but also determined to be a key regulator in 
controlling apoptosis among several of the TNF ligands (Aggarwal, 2003).   NF-κB involvement 
in protection from apoptosis was most prominently shown in p65-/- mice, which die at embryonic 
day E (15) due to excessive apoptosis of hepatocytes (Beg et al., 1995).   NF-κB suppression of 
apoptosis is a result of gene induction and extensive research is directed towards understanding 
  45 
the anti-apoptotic genes regulated by NF-κB (Karin and Lin, 2002).  NF-κB suppression of 
apoptosis is a result of gene induction and extensive research is directed towards the 
understanding of anti-apoptotic genes regulated by NF-κB. Notable NF-κB responsive genes 
include the c-IAP family of proteins known to prevent the proteolytic processing pro-caspases -3, 
-6, and -7 (Deveraux et al., 1998). The adaptor protein c-FLIP is another well-characterized anti-
apoptotic factor that is regulated by NF-κB. c-FLIP interacts with FADD and procaspase-8 and 
prevents the initiation of caspase pathway (Kreuz et al., 2001). Other notable NF-κB inducible 
factors include the Bcl-2 family members Bcl-2 and Bcl-XL which are known for maintaining 
the integrity of the mitochondrial membrane (Lee et al., 1999; Tamatani et al., 1999). Thus, there 
are number of genes that might be involved in VEGI-induced NF-κB activation and it will be of 
future interest to determine which factor(s) is important in suppressing apoptosis mediated by 
VEGI in endothelial cells. 
 For this investigation we utilized siRNA for a highly specific approach to prevent 
activation of the canonical NF-κB pathway. A possible disadvantage of silencing either p65 or 
IKK2 could be the depletion of basal survival factors required for normal cell integrity. An 
advantage of the small-molecule inhibitors is their brief introduction (2 h) can result in a rapid 
disabling of the NF-κB pathway. Thus, providing a short time frame between the inhibition of 
the NF-κB pathway and the exposure to VEGI, minimizing possible adverse cellular effects that 
could come about in the long-term suppression of the NF-κB pathway. The siRNA and the small-
molecule inhibition data therefore provide complimentary results that helped to clarify inducible 
NF-κB activation.  
 We were able to establish that endothelial cells became sensitized to VEGI in the presence 
of NF-κB inhibitors. We showed a decrease in the IC50 value of VEGI in the presence of either 
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curcumin or BMS-345541. The use of NF-κB inhibitors to improve the efficacy of several 
anticancer agents is under investigation (Nakanishi and Toi, 2005). Another member of the TNF 
family, TNF-related apoptosis-inducing ligand (TRAIL), is a promising cancer therapeutic and 
efforts are directed to use this ligand in combination with NF-κB inhibitors to improve this 
cytokine’s therapeutic potential (Romagnoli et al., 2007; Shankar et al., 2008).  VEGI is an 
promising anti-angiogenic therapeutic shown to be effective in inhibiting tumor growth in 
several murine models including a colon cancer model (Zhai et al., 1999a), a prostate cancer 
model (Zhai et al., 1999a), a xenograft breast cancer model (Zhai et al., 1999b), and a Lewis lung 
carcinoma model (Hou et al., 2005).   The efficacy of VEGI to inhibit tumor growth is thought to 
be primarily attributable to the inhibition of tumor angiogenesis. Anti-angiogenic agents such as 
VEGI are of principal importance in cancer research as well in research of several vascular 
diseases such as infantile hemangiomas, peptic ulcers, ocular neovascularization (Folkman, 
2007).   Our studies reveal that the synergy between VEGI and NF-κB inhibitors increases the 
potency of VEGI to initiate endothelial cell death. Further analysis of in vivo models will be of 
interest to determine if a similar synergy is observed in reducing blood vessel growth in tumor 
models and other vascular disease states.  
  In conclusion, we show that inhibition of VEGI-induced activation of the predominant NF-
κB complex results in an increased apoptotic potential of VEGI. It is thus plausible that inducible 
NF-κB activation suppresses VEGI-induced endothelial cell apoptosis. 
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3.1  ABSTRACT 
 Death receptor-3 (DR3; TNFRSF25) is a receptor for VEGI for T cells; however, it is yet 
to be determined if DR3 is the receptor responsible for VEGI-mediated endothelial cell death.  In 
addition, it is unknown if different VEGI isoforms utilize the same receptor to mediate their 
cellular activities.  Here investigated if DR3 is the necessary receptor required for VEGI-
mediated endothelial cell apoptosis.  We used RNA interference (RNAi) to silence expression of 
the DR3 gene in ABAE cells and determined how this affected the activities of two VEGI 
isoforms: VEGI-192 and VEGI-251. We found that DR3-depleted endothelial cells exhibited a 
markedly diminished responsiveness toward the cytotoxic and apoptosis-inducing activity of 
both VEGI isoforms. Interestingly, we obtained similar results with lipopolysaccharide (LPS) 
and TNFα as both of these factors were also unable to mediate endothelial cell death in DR3-
depleted cells. However, treatment of DR3-depleted cells with the chemotherapeutic, 
doxorubicin, resulted in a similar decrease in cell viability as compared to the control cells. We 
also found that VEGI-192 treatment on DR3-depleted cells resulted in an enhanced activation of 
NF-κB.  These data reveal that depletion of DR3 from ABAE cells had a unique impact on the 
cells. These data suggest DR3 is regulating a critical component(s) in the extrinsic apoptosis-
inducing pathways mediated by VEGI, LPS, and TNFα.  We hypothesize during normal cell 
growth DR3 is involved in repressing the NF-κB pathway, such that the siRNA depletion of DR3 
from the cells results in an increased amount of activated NF-κB which then leads to an 
enhanced pro-survival in the cells.  We determined a novel role of DR3 in the regulation of the 
apoptotic pathway however do to these unexpected results we cannot confirm a ligand-receptor 
relationship between VEGI and DR3  
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3.2  INTRODUCTION 
VEGI is a type II transmembrane protein belonging to the TNF superfamily of ligands (Yue et 
al., 1999). The human VEGI gene spans about 17 kb and consists of four exons with three VEGI 
transcripts generated by the use of cryptic splice sites and alternate exons (Chew et al., 2002).  
The three isoforms results in peptides containing 174aa, 192aa, and 251aa so denoted by their 
amino acid count.  The VEGI-174 isoform contains transmembrane domain suggesting a 
membrane-bound variant of VEGI.  The VEGI-192 does not contain a transmembrane domain 
nor a secretory domain and it is unclear of the subcellular localization of the protein. The VEGI-
251/TL1A isoform encodes a 251aa peptide that contains a secretory signal peptide at the N-
terminus, upon cleavage of the signal peptide the remaining 179aa peptide exists as soluble 
variant of VEGI (Migone et al., 2002). These alternatively spliced isoforms differ in a small 
stretch of amino acids at the their N-terminus, however all isoforms share the 151 aa stretch of 
amino acids known as the TNF homology domain (THD), a domain common to other TNF 
ligands that is known to be responsible for receptor binding.  Expression of the VEGI THD 
domain (1-151aa) alone is able to inhibit endothelial cell growth (Wang et al., 2000). 
 VEGI is a ligand for two receptors belonging to the TNFR superfamily of receptors: decoy 
receptor 3 (DcR3) and death receptor 3 (DR3) (Migone et al., 2002). DcR3 is a soluble receptor 
thought to be a negative regulator of cell signaling (Roth et al., 2001). DR3 is a cell-surface 
receptor capable of mediating cellular activities. Sequence homology of DR3 reveals that it is 
closely related to TNFR1 and is characterized by cysteine-rich domains common to other TNFR 
receptors (Marsters et al., 1996). DR3 belongs to a subset of the TNF receptor family that 
contains an intracellular death domain capable of activating the caspase pathway. DR3 is 
enriched in immune cells and ectopic expression of DR3 results in the aggregation and 
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recruitment TNFR-1 associated death domain (TRADD) protein and Fas-associated domain 
containing (FADD) protein as downstream effectors of apoptosis (Kitson et al., 1996; Screaton et 
al., 1997). 
 It is yet to be determined if DR3 is the leading receptor responsible for mediating the 
inhibitory activities of VEGI on endothelial cells. Here we sought to determine a functional 
ligand/receptor relationship between VEGI and DR3 in endothelial cells.  We found that two 
VEGI isoforms could no longer initiate apoptosis in ABAE cells that had been depleted of DR3 
by siRNA. Surprisingly, we also found that both LPS and TNFα, which are not known to be the 
ligands of DR3, were similarly unable to induce apoptosis in DR3-depleted endothelial cells. We 
also determined that VEGI-induction of NF-κB was not diminished in DR3-silenced cells, but 
was rather enhanced in DR3-depleted cells. We hypothesize that DR3 is a negative modulator of 
NF-κB activation and the removal of DR3 is causing an increased propensity for NF-κB activity. 
It is likely an increase in NF-κB activity would then result in an increased expression of anti-
apoptotic genes and fortify the cells from various apoptotic stimuli.  We also speculate that since 
VEGI continues to sufficiently induce NF-κB in DR3-depleted cells that VEGI may be utilizing 
an unidentitfied receptor in endothelial cells.  
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3.3  MATERIALS AND METHODS 
3.3.1  Cells and reagents 
Adult bovine aortic endothelial (ABAE) cells were purchased from Lonza (Walkersville, MD) 
and maintained in endothelial growth medium  (EGM-MV) media. ABAE cells were used in 
passages 4-10.   DR3 (NT) mouse polyclonal antibody was purchased from ProSci (Santa Cruz, 
CA). TNFα was purchased R&D systems (Minneapolis, MN) LPS was purchased from Sigma-
Aldrich (St. Louis, MO). VEGI-192 was prepared as previously described (Tian et al., 2007). 
VEGI-251 was prepared as previously described (Jin et al., 2007a).  
3.3.2  siRNA transfection 
 Custom designed siRNA were synthesized by Sigma-Proligo (St. Louis, MO). siRNA sequences 
were designed against the bovine DR3 mRNA: DR3 siRNA-1 5'- CGGGAAAACCACTACG 
AAA-3', and DR3 siRNA-2 5'-GCCCTAAGTACGGTTACTT-3'. A scrambled siRNA control 
was purchased from Ambion (Austin, TX).  siRNA duplexes were complexes with 
Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA) diluted and plated in opti-MEM reduced 
serum medium. 100 nM of siRNA was added with Lipofectamine RNAiMax at a ratio of 40:1 of 
pMol to lipid mixture.  Transfections proceeded overnight at 37 ºC, 5% CO2  after which the 
cells were placed back in normal growth media.   
3.3.3 Western Blot analysis 
Cells were subjected to lysis in a buffer containing 50 mM Tris-HCl pH 7.4, 250 mM NaCl, 5 
mM EDTA, 0.1% Nonidet P-40, 0.5% Sodium Deoxycholate, and a protease inhibitor cocktail 
(Roche Applied Science, Indianapolis, IN).  Total protein lysate was resolved using 12% SDS-
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PAGE. The proteins were then transferred onto a Hybond-ECL nitrocellulose membrane, 
blocked with 5% nonfat dried milk powder in TBST buffer (20 mM Tris-HCl (pH 7.4), 137 mM 
NaCl, and 0.1% Tween 20) for 1 hour at room temperature, and incubated overnight at 4 ºC with 
primary antibodies against the target protein.  The membrane was then washed and incubated 
with the appropriate HRP-conjugated secondary antibody, washed with TBST, and developed 
with the ECL system (Amersham Biosciences, Pittsburgh, PA).  
3.3.4  Viability assay 
 ABAE cells were seeded in black 96-well well plates. Following the treatments, the cells were 
washed once with PBS.  Calcein-AM (Invitrogen Carlsbad, CA) 1 µg/ml in PBS was then added 
to the cells and incubated for 30 minutes at room temperature. The cells were washed with PBS 
and fluorescent intensity, 485nm excitation: 520 nm emission was measured on a Tecan Safire 
fluorescence plate reader (Tecan, San Jose, CA) 
3.3.5  Caspase-3 substrate assay 
 ABAE cells were seeded in 96-well plates and following treatments 25 µl of lysis buffer was 
added directly to the plate and incubated for 2 hours at 4 ºC on a shaker. Plates were then 
centrifuged and cleared lysates were transferred to a new 96-well plate.  For each well containing 
25 µl cleared lysates was added 12.8 µl of Caspase buffer (312.5 mM HEPES Ph 7.5, 31.25% 
w/v sucrose, 0.3125% w/v CHAPs), 0.8 µl of DMSO, 4 µl of 100 mM DTT, 6.6 µl dH2O and 0.8 
µl of 10 mM DEVD-pNA substrate (BioVision, Mountain View, CA). Plates were incubated 
overnight at 37 ºC and plates and then read at 405 nm with a Benchmarked Plus microplate 
reader (Biorad, Hercules, CA). 
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3.3.6  DNA fragmentation assay 
 ABAE cells were seeded in 96-well plates and following treatments the cells were subjected to 
the apoptosis detection kit TiterTACS™, Trevigen (Gaithersburg, MD) following the 
manufacture’s protocol. TiterTACS™ detects DNA double strand breaks using the in situ 
terminal deoxynucleotidyl transferase (TUNEL) assay followed by colorimetric analysis.  
Absorbance was measured at 450 nm with a Benchmarked Plus microplate reader.  
3.3.7  Nuclear translocation assay 
 Translocation of NF-κB from cytoplasm to nucleus was analyzed using an automated 
fluorescence imaging system.  ABAE cells were cultured in a black 96-well plate and following 
treatments the cells were fixed with 4% paraformaldehyde for 10 min. The cells were then 
permeabilized with PBS containing 1% Triton X-100 for 5 min. NF-κB was labeled by adding 
mouse anti-p65 antibody and Alexa Fluor 488 goat anti-mouse antibody (Invitrogen, Carlsbad, 
CA). Nuclei were stained with 1 mg/ml Hoechst 33342. Cellomics ArrayScan VTI HCS Reader 
analyzes fluorescent intensity (mean pixel intensity) of nuclear and cytoplasmic regions 
according to the target channel (488 nm) using a defined algorithm.   
3.3.8  QRT-PCR 
 Total RNA was extracted and purified from cultured ABAE cells by an RNeasy mini-kit 
(Qiagen, Valencia, CA). RT was performed in 100 µL reaction volumes with random hexamer 
priming using the TaqMan® One-Step RT-PCR Kit  (ABI systems, Foster City, CA). The 
expression levels of the genes for IL-6, IL-8, and GAPDH were amplified using SYBR® Green 
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kit (ABI Systems) and quantitative real time polymerase chain reaction was performed on ABI 
PRISM 7700 sequence detection system. Primers sequences were as follows; IL-6 Forward 5'-
TGA GTG TGA AAG CAG CAA GGA-3' reverse 5'-TCG CCT GAT TGA ACC CAG ATT-3', 
IL-8 Forward 5'-GAAGAGAGCTGAGAAGCAAGA -3' Reverse 5'-ACCCACACAGAACA 
TGAGGC -3', GAPDH Forward 5'-GGC GTG AAC CAC GAG AAG TAT-3' Reverse 5'-CCT 
CCA CGA TGC CAA AG TG-3'. Relative expression of the marker genes was calculated from 
the delta-Ct (threshold cycle) of the targeted gene normalized to the delta-Ct of GAPDH. 
3.3.9  Statistical Analysis 
A one-tailed Students t test was used for comparison of two groups. Significance was defined as 
P<0.05 
 
3.4.  RESULTS 
3.4.1   siRNA inhibition of DR3 expression 
In order to deplete DR3 from ABAE cells we used RNA interference technology. We designed 
two siRNA that targeted different sites of the bovine DR3 mRNA. Western blot analysis showed 
that the siRNA treatments of ABAE cells with DR3 siRNA-1 and siRNA-2 were effective at 
silencing DR3 gene expression (Figure 16A). Densitometry analysis showed that cells 
transfected with DR3 siRNA-1 and siRNA-2 exhibited a 65% and 85% decrease, respectively, of 
DR3 protein levels as compared to the scrambled control cells (Figure 16B).  
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Figure 16. siRNA depletion of DR3 from ABAE Cells.  ABAE cells were transfected 
with DR3 siRNA (100nm) targeting two different regions along the bovine DR3 mRNA. A, 
Western blot analysis of DR3 72 h following the transfection. β-actin was used as loading 
control. B, Densitometric analysis of the blot.  
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3.4.2  DR3-depleted ABAE cells are protected from the cytotoxcity exhibited by the VEGI 
isoforms 
We next determined how DR3-silencing in ABAE cells affected the cytotoxicity of VEGI-192 
and VEGI-251.   Forty-eight hours following the transfection with the respective siRNA, ABAE 
cells were exposed to either recombinant VEGI-192 or VEGI-251 for 48 hours. The cells were 
then subjected to a calcein viability assay. Figure 17A, VEGI-192 exposure to the scramble 
siRNA treated cells exhibited a dose-dependent decrease in cell viability, achieving an 
approximately 70% decrease in cell viability with the highest dose of VEGI (2 units). VEGI-192 
exposure to ABAE cells transfected with DR3 siRNA-1 achieved an approximate 45% reduction 
in cell viability with 0.5 VEGI units and there was only a minimal decrease in viability with 
further VEGI concentrations. VEGI-192 exposure to the ABAE cells transfected with DR3 
siRNA-2 showed a 25% reduction with 0.25 VEGI units and no further decrease in viability was 
observed through the highest dose of VEGI (2 units). We repeated experiment using the VEGI-
251 isoform (Figure 17B). VEGI-251 exposure to the scrambled siRNA treated cells exhibited a 
dose-response and achieved a 50% decrease in cell viability with 1 unit of VEGI. VEGI-251 
exposure to the ABAE cells treated with DR3 siRNA-2 only achieved a 15% decrease in cell 
viability through the highest concentration of VEGI (2 units).    These results indicate that ABAE 
cells depleted of DR3 are less responsive to the cytotoxicity of both VEGI isoforms.   
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Figure 17. Reduced VEGI-cytotoxicity in DR3-depleted cells. Viability of DR3-
silenced ABAE cells following treatment with the VEGI isoforms. A, Cells were transfected 
with scrambled siRNA (closed circles), DR3 siRNA-1 (open squares) or DR3 siRNA-2 (open 
triangles) then treated with VEGI-192 at indicted concentrations for 48 hours and 
subjected to a calcein assay. B, Viability of ABAE cells treated with scrambled siRNA 
(closed circles) or DR3 siRNA-2 (open triangles) then treated with VEGI-251 for 48 hr and  
subjected to a calcein assay. Values are means ± SD of duplicate measurements. Data are 
from a typical experiment of at least two independent experiments. 
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3.4.3 DR3 depletion from ABAE cells attenuates apoptosis initiated by the VEGI isoforms  
VEGI reduces ABAE cell viability by inducing apoptosis we therefore determined the 
apoptotic potential of VEGI-192 and VEGI-251 in DR3-depleted cells.    We first measured 
activation of caspase-3, a hallmark of apoptotic induction.  ABAE cells were transfected with the 
respective siRNA for 72 h and then exposed to various concentrations of VEGI-192 for 9 h. 
Whole cell lysates were extracted and subjected to a caspase-3 substrate (DEVD) assay (Figure 
18A).  Treatment of VEGI-192 on cells depleted of DR3 using siRNA-1 or siRNA-2 showed a 
marked reduction of activated caspase-3 as compared to the scrambled control treated cells 
resulting in a 40% and 60% inhibition, respectively, of activated caspase-3 at 2 units of VEGI.  
We next treated DR3-depleted cells with the VEGI-251 isoform and performed a caspase-3 
substrate assay (Figure 18B). Exposure to VEGI-251 on the control siRNA treated cells 
exhibited a dose-response having an approximately 3-fold increase of caspase-3 activation at the 
2 units of VEGI. Treatment of VEGI-251 on DR3-depleted cells using siRNA-2 showed a 
minimal effect on caspase-3 activation with increasing VEGI concentrations.  
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Figure 18. DR3-depletion from ABAE cells attenuates VEGI-induced caspase-3 
activation. A, ABAE cells were transfected with scrambled siRNA (closed circles) or DR3 
siRNA-1 (open squares) or DR3 siRNA-2 (open triangles) then treated with VEGI-192 at 
indicated concentrations for 9 h and subjected to a caspase-3 substrate assay. B, ABAE 
cells transfected with scrambled siRNA (closed circles) or DR3 siRNA-2 (open triangles) 
then treated with VEGI-251 at indicated concentrations for 9 h and subjected to a caspase-
3 activation assay. Values are means ± SD of duplicate measurements. Data are from a 
typical experiment of at least two independent experiments. 
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In addition to the caspase-3 assay we measured DNA fragmentation for a second 
measurement of apoptosis.  ABAE cells were transfected with the scrambled siRNA or DR3 
siRNA-2 then treated with VEGI-192 and subjected to a TUNEL assay (Figure 19A).  Treatment 
of VEGI-192 showed a 90% reduction of the amount of DNA fragmentation as compared to the 
scrambled control cells. We also performed a TUNEL assay with VEGI-251 treatment on DR3-
depleted cells (Figure 19B).  Treatment of VEGI-251 on DR3-depleted cells showed minimal 
changes in DNA fragmentation as compared to the scrambled control cells.  The caspase-3 and 
TUNEL assays showed that both VEGI isoforms are unable to facilitate apoptosis in DR3-
depleted cells.  
 
Figure 19.  DR3-depletion from ABAE cells attenuates VEGI-induced DNA fragmentation. 
A and B, ABAE cells transfected with scrambled or DR3 siRNA-2 then treated with the 
indicated VEGI isoform for 9 h and subjected to a TUNEL assay. Values are means ± SD of 
duplicate measurements; **P<0.001. Data are from a typical experiment of at least two 
independent experiments. 
  62 
3.4.4  DR3 depletion of ABAE cells attenuates the cytotoxicity mediated by LPS and 
TNFα  but not doxorubicin 
We next determined if the loss of VEGI activity on DR3-depleted cells described above was 
specific.  As a negative control to determine specificity we chose LPS, a component of the outer 
membrane of Gram-negative bacteria. LPS, acting through toll-like receptor 4, induces apoptosis 
and initiates cellular activity in endothelial cells similar to VEGI (Choi et al., 1998). Following 
treatments with the respective siRNA, the cells were treated with various concentrations of LPS 
and subjected to a calcein viability assay (Figure 20A). LPS treatment on the scrambled controls 
cells led to about a 50% decrease in endothelial cell viability. LPS treatment on the DR3-
depleted cells only led to about a 20% decrease in endothelial cell viability and no further 
decrease in cell viability was shown with increasing concentrations of LPS.  We next determined 
if LPS could mediate apoptosis in DR3-depleted endothelial cells. Cells were treated with the 
respective siRNA, then treated with LPS for 9 h and analyzed for caspase-3 activity (Figure 
20B).  LPS treatment on the scrambled siRNA-treated control cells led to a 3-fold increase in 
caspase-3 activation. LPS treatment on the DR3-depleted cells resulted in a 75% reduction of 
activated caspase-3. These results indicate that DR3-depleted endothelial cells are protected from 
LPS-induced apoptosis.  
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Figure 20. DR3-depletion from ABAE cells attenuates LPS mediated endothelial cell 
death. A, Viability of ABAE cells exposed to LPS.  ABAE cells were transfected with 
scrambled siRNA (closed circles) or DR3 siRNA-2 (open squares) then treated with LPS at 
indicated concentrations for 48 h and subjected to a calcein assay. B, Caspase activation 
following LPS exposure to DR3-depleted cells.  ABAE cells were transfected with 
scrambled or DR3 siRNA-2 then treated with LPS (1µg/ml) for 9 h and subjected to a 
caspase-3 substrate assay. Values are means ± SD of duplicate measurements; **P<0.001. 
Data are from a typical experiment of at least two independent experiments. 
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To further investigate if other apoptotic stimuli are able to mediate cell death in DR3-depleted 
cells we investigated TNFα and doxorubicin activity on ABAE cells.  TNFα is able to induce 
apoptosis in endothelial cells through TNFR-1 and possibly shares very similar signaling 
components with VEGI-induced pathways (Hsu et al., 1996). Doxorubicin is a chemotherapeutic 
that intercalates in DNA to interrupt DNA synthesis, resulting in apoptosis (Oyarzo et al., 2006). 
Cells were transfected with the respective siRNA, treated with various concentrations of either 
TNFα or doxorubicin, and then subjected to a calcein assay.  Figure 21A, TNFα exposure to the 
scramble control siRNA-treated cells resulted in a 70% reduction in viability.  TNFα treatment 
exposure to the DR3-depleted cells only achieved a 25% reduction in cell viability with the 
highest concentration used.  In sharp contrast, doxorubicin treatment of both the scrambled 
control siRNA-treated cells and the DR3-depleted cells led to a similar decrease in viability 
(Figure 21B).  These results suggest the DR3-depleted endothelial cells are resistant to certain 
stimuli that are known to activate the extrinsic apoptotic pathway, but not those that stimulate the 
intrinsic apoptotic pathway.  
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Figure 21. DR3-depletion from ABAE cells attenuates TNF but not doxorubicin mediated 
ABAE cell death. A and B, ABAE cells transfected with scrambled (closed circles) and DR3 
siRNA-2  (open squares) treated with indicated stimuli at various concentrations. Values 
are means ± SD of duplicate measurements.  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3.4.5  DR3-depletion increases VEGI-192 stimulated NF-κB activation 
To investigate if DR3 has a role in the activation of VEGI cellular activities other than apoptosis 
we next investigated activation of NF-κB. ABAE cells were treated with the respective siRNA 
then treated with VEGI-192 and subjected to a NF-κB p65 nuclear translocation assay (Figure 
22A).  VEGI exposure to the scrambled control siRNA-treated cells exhibited a dose-response 
showing a 2-fold increase of nuclear NF-κB concentrations with 2 units of VEGI as compared to 
the untreated cells.  VEGI exposure to the DR3-depleted cells exhibited a similar dose-response 
with approximately a 3-fold increase in nuclear NF-κB concentrations with 2 units of VEGI as 
compared to the untreated cells. When comparing the cells treated with scrambled or DR3 
siRNA in the absence of VEGI there was a slight increase in nuclear NF-κB levels in the DR3 
siRNA treated cells.  We next quantified the cytoplasmic levels of NF-κB p65 from the same 
experiment to determine if there was a difference of p65 levels in resting cells of the two siRNA-
treated groups (Figure 22B).  We determined approximately a 25% increase in the cytoplasmic 
levels of p65 in the DR3-depleted cells as compared to the scrambled control group. These 
results indicate that VEGI is able to sufficiently activate NF-κB when cells are depleted of DR3. 
Additionally, DR3-depletion from ABAE cells results in a slightly higher concentration of NF-
κB p65 concentrations in the nucleus and in the cytoplasm.  
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Figure 22. Enhanced NF-κB activity in DR3-depleted cells.  A, Nuclear levels of 
activated NF-κB following siRNA and VEGI (2 units, 30 min) treatment. Cells were 
fluorescently labeled for p65 and subjected to automated fluorescent imaging analysis to 
determine fluorescent intensity of nuclear p65. B, Cytoplasmic analysis of NF-κB p65 levels 
of cells transfected with scrambled siRNA or DR3 siRNA-2. Values are means ± SEM of 
duplicate measurements. At least 3000 cells were analyzed. Data are from a typical 
experiment of at least two independent experiments. 
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To further investigate enhanced activation of NF-κB in DR3 depleted cells we determined the 
expression levels of the NF-κB-target genes, IL-6 and IL-8 following exposure to VEGI.  Cells 
were transfected with the respective siRNA, then exposed to VEGI-192 for 7 hours and 
subjected to qRT-PCR analysis of IL- and IL-8. Figure 23A, VEGI exposure to the scrambled 
control siRNA-treated cells led to a 50-fold increase in IL-6 expression levels. VEGI exposure to 
the DR3-depleted cells led to approximately a 150-fold increase in IL-6 expression levels .  
Figure 23B, VEGI-192 exposure to the control siRNA treated cells led to approximately a 200-
fold increase in IL-8 expression levels. VEGI-192 exposure to the DR3-depelted cells lead to 
approximately a 600-fold increase in IL-8 expression levels.  These results further establish 
enhanced NF-κB activity in response to VEGI.   
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Figure 23. Increased expression NF-κB regulate genes in DR3-depleted cells. A, 
Quantitative RT-PCR analysis of IL-6 expression in ABAE cells following treatment with 
the indicated siRNA and VEGI (2 units, 7 h). Β ,  Quantitative RT-PCR analysis of IL-8 
expression in ABAE cells following treatment with the indicated siRNA and VEGI (2 units, 
7 h). 
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3.5  CONCLUSIONS 
 
Here we investigated if DR3 is the receptor responsible for VEGI-induced endothelial cell death. 
Interaction of VEGI-251 with DR3 was convincingly shown by flow cytometry analysis, co-
immunoprecipitation, and Biacore analysis (Migone et al., 2002).  However, the VEGI 
preparation used in the Migone et al. investigation did not exhibit any inhibitory actions towards 
endothelial cells and hence no direct correlation was made between the VEGI-251/DR3 
interaction and endothelial cell bioactivity. Migone et al. suggested that the VEGI-174, but not 
VEGI-251, can inhibit endothelial cell growth while. Thereby raising the notion that there may 
be an endothelial-specific receptor for VEGI-174. Another inconsistency surrounding VEGI and 
DR3 interaction in endothelial cells relates to the DR3 expression pattern in human tissue. VEGI 
has a prominent role in regulating the vasculature however DR3 is mainly enriched immune 
cells. Suggesting there may a more functionally related receptor expressed in endothelial cells 
that accounts for the role of VEGI in vascular biology. Although, it is known that human 
umbilical cord endothelial cells express DR3 (Chinnaiyan et al., 1996) and here we report DR3 
expression in ABAE cells, the presence of a receptor is not conclusive to determine a functional 
significance between a ligand and receptor.  Furthermore, the TNF families of ligands are known 
to bind to multiple receptors for cell signaling. For instance, TNFα binds to TNFR-1 and TNFR-
2 and the TRAIL ligand binds to DR4 and DR5. Therefore, it is a characteristic of the TNF 
family ligands to bind multiple receptors.  
 Recent studies provide some evidence for the notions that VEGI isoforms may interact to 
different receptors. Analysis of the x-ray crystal structure of VEGI-251 predicts a very different 
AA’ loop in comparison to the VEGI-174 isoform as a result in differences in the N-terminus 
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sequences (Jin et al., 2007a).  The AA’ loop is important for receptor binding in the TNF family 
member, TRAIL. Therefore it is suggestive that the AA’ loop among different isoforms can 
result in alterations in the receptor binding domain and possibly affect the specificity for a 
receptor.  Another recent study provides evidence to the notion that VEGI binds to multiple-
receptors. Al-Lamki et al found VEGI can mediate apoptosis, induce NF-κB activation, and 
regulate TNFR expression in isolated kidney cultures (Al-Lamki et al., 2008).  In DR3-/- 
knockout mice VEGI was no longer able to induce apoptosis or activate NF-κB however VEGI 
was still able to regulate TNFR expression. Thus, apoptosis and NF-κB activation can be 
attributed to signaling via DR3 yet VEGI continued to regulate TNFR expression in the absence 
of DR3 suggesting that VEGI is utilizing a different receptor for some cellular activities.  
 In order to investigate the receptor that mediates endothelial cell death initiated by VEGI 
we first investigated if DR3 is the responsible receptor.  We determined that in cells depleted of 
DR3, two VEGI isoforms could not mediate endothelial cell apoptosis. Initially we understood 
these data to represent our hypothesis that DR3 is in fact the receptor utilized by VEGI to initiate 
endothelial cell death. However, when DR3-depleted endothelial cells were treated with either 
LPS or TNFα these apoptotic stimuli also could not induce apoptosis.  Direct binding studies 
with TNFα and DR3 report that TNFα is not a ligand for DR3 (Bossen et al., 2006).  LPS, 
known to bind to toll-like receptor 4, does not contain a TNF homology domain and therefore 
there is no precedence for LPS to bind to members of the TNF receptor family (Fenton and 
Golenbock, 1998). So it is unlikely that TNFα and LPS are in endothelial cells in a very similar 
fashion (Frey and Finlay, 1998; Messmer et al., 1999). Thus, a possible reason for the observed 
loss of action from LPS and TNFα on DR3-depleted from endothelial cells is because the 
apoptotic pathway is nonfunctional.  
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 There are at least two possibilities that DR3-depletion may have rendered the apoptotic 
pathway nonfunctional. The first is constitutive activation of DR3 could be regulating an 
essential factor(s) in the apoptotic pathway.  Thus, removal of DR3 from the cells would removal 
this factor resulting in a gap in the apoptotic pathway. A second possibility for the nonfunctional 
apoptotic pathway may come about if DR3 is involved in downregulating certain pro-survival 
factors. Thus, following the removal of DR3 these factors would become upregulated and lead to 
enhance suppression of the apoptotic pathway.   
 A response to the first possibility, that DR3 is involved in regulating an essential factor, we 
observed no protective effect in DR3-depleted cells from doxorubicin. This suggests that cells 
depleted of DR3 contain the necessary molecules to complete the apoptotic pathway initiated by 
this stimuli. Doxorubicin induces apoptosis via the intrinsic apoptotic pathway (Oyarzo et al., 
2006). So there will some differences in the apoptotic molecules involved in the apoptotic 
pathway mediated by doxorubicin as compared to the other tested stimuli, which induce 
apoptosis via the extrinsic apoptotic pathway. There are some overlapping molecules used both 
pathways such as caspase-3, so the ability of doxorubicin to initiate cell death in the DR3-
depleted cells suggest that removal of DR3 is not affecting certain downstream effector apoptotic 
molecules. However, this does leave the possibility that DR3 is able to regulate an apoptotic 
molecule that is involved in the extrinsic pathway. For example the adaptor protein FADD is a 
molecule used by all LPS, TNFα, and VEGI but is not used in the intrinsic pathway (Choi et al., 
1998; Baud and Karin, 2001; Wen et al., 2003).   
 A response to the second possibility, that DR3 is downregulating a pro-survival factor, we 
show that there is enhanced NF-κB activation following VEGI exposure to DR3-depleted ABAE 
cells. In Chapter 2 we determined that activation of NF-κB is suppresses the apoptotic pathway. 
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It follows that if there were an increase in NF-κB activation then there would be an increased 
suppression of the apoptotic pathway.  Although the data we present here involves VEGI-
induced NF-κB activity, it should be noted that both LPS and TNFα can also induce NF-κB in 
endothelial cells and it is possible that there are increased levels of NF-κB activation following 
the treatment with these stimuli.  Our preliminary data suggests that increased NF-κB activity in 
DR3-depleted cells could at least play a partial role in protecting these cells from several 
apoptotic stimuli and possible be the only mechanism involved.   
 One question arises if the mild to moderate increase in NF-κB activity in DR3-depleted 
cell would be sufficient enough to exhibit the observed protective effect. It is possible the 
moderate increases in NF-κB activation could result in an amplified suppression effect on the 
apoptotic pathway. We show that VEGI regulation of IL-6 and IL-8 genes revealed a 2-fold 
further increase in expression levels in DR3-depleted cells as compared to control cells.   It is 
quite possible that other NF-κB-target genes are similarly enhanced. NF-κB is capable of 
upregulating several anti-apoptotic factors and it is possible that these factors work 
simultaneously to shut down the apoptotic pathway. Further investigations would be of interest 
to determine if the enhanced NF-κB activity in DR3-depleted cells is the mechanism resulting in 
the resistance from several apoptotic stimuli.  
 These findings give preliminary evidence in a novel role of DR3 to control the apoptotic 
potential of several stimuli. However, the question still remains whether or not DR3 is the major 
endothelial-cell receptor for VEGI. Due to the unexpected effect of depleting DR3 from the cells 
it is difficult to ascertain a functional relationship between VEGI and DR3 as a ligand receptor 
pair.  One pertinent observation is the fold-induction of NF-κB following VEGI exposure to 
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DR3-depleted cells.  If DR3 is the sole receptor in endothelial cells we would expect depletion of 
DR3 to exhaust the ability of VEGI to activate NF-κB.  Since VEGI continues maintain a 
significant effect on fold-induction of NF-κB suggesting that there is an alternate receptor 
mediating VEGI-induced NF-κB activation.   Future investigations to determine unknown VEGI 
receptors should be a focus. Protein/protein interactions may be the most useful studies to help 
determine unknown receptors, after which further investigations of the functional significance of 
each receptor can be done.    
 In conclusion we were unable to establish a functional relationship between VEGI and 
DR3 on the cell-surface of endothelial cells. However, we did unravel two important findings. 
First, that DR3 is involved in controlling the extrinsic apoptotic pathway under normal 
conditions, possibly through deregulating the NF-κB pathway. Second, we provide preliminary 
evidence of VEGI having multiple-receptors in endothelial cells.   
 
 
 
 
 
 
 
 
 
  75 
 
4.0  DISCUSSION  
The emphasis of this thesis was to investigate the molecular mechanisms of VEGI activity on 
endothelial cells. We focused on the NF-κB pathway and the identification of the receptor used 
in VEGI-mediated endothelial cell death in order to gain a better understanding of VEGI 
signaling. The receptor study interestingly led us back to an investigation of NF-κB. Thus, 
emphasizing the intimate relationship between NF-κB and members of the TNF superfamily. 
Due to it role in multiple biological processes and its association with several human diseases 
multiple NF-κB is one of the most extensively studied molecules.  
4.1 VEGI SPECIFICITY TOWARDS ENDOTHELIAL CELL DEATH  
  
4.1.1  VEGI-stimulated NF-κB activation in Endothelial cells and TF-1 cells 
  One of the more prominent roles of NF-κB is its regulation of apoptosis. In Chapter 2 we 
established such a role of NF-κB in VEGI-mediated signaling. When we inhibited NF-κB 
pathway using either siRNA or small-molecule inhibitors there was an increase in VEGI-induced 
endothelial cell death. These results suggest that NF-κB during normal activation by VEGI 
exhibits an anti-apoptotic role in endothelial cells.  It should be noted that this anti-apoptotic role 
is not sufficient to prevent VEGI-mediated endothelial cell death. In a previous report describing 
VEGI signaling in the erythroleukemic cell line, TF-1, NF-κB was determined to suppress the 
apoptosis  (Wen et al., 2003). VEGI-induced NF-κB activation in TF-1 cells is able to prevent 
cell death.  Figure 24 shows cell models summarizing our study of VEGI signaling in endothelial 
cells and the previous report of VEGI signaling in TF-1 cells. VEGI is known to stimulate 
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multiple cell-types including T cells, macrophages, dendritic cells. However, only in endothelial 
cells is cell death the result following VEGI stimulation. It is possible that NF-κB activation is a 
determining factor in the specificity of VEGI’s cytotoxicity towards different cell-types.  NF-κB 
may act as a guard on the apoptotic pathway and only in endothelial cells will the VEGI response 
be allowed to complete the apoptotic pathway and result in cell death.  
 
Figure 24. VEGI signaling in endothelial cells versus TF-1. As determined in Chapter 2, 
VEGI signaling leads to activation of NF-κB and the Caspase pathway.  NF-κB activation 
suppresses apoptosis however cell death still pursues. In a previous report VEGI 
stimulation of TF-1 cells also leads to NF-κB and caspase activation however the NF-κB 
response is able block the apoptotic pathway and prevent cell death.   
  77 
 
4.1.2  Mechanisms to control NF-κB activity 
 We state that NF-κB activity may be used to control VEGI specificity. It is unclear how 
VEGI can utilize NF-κB for only a partial affect on the apoptotic pathway in one cell-type and 
the complete suppression of the pathway in another cell-type. Several mechanisms are reported 
to help understand the control of NF-κB activity.   
 Each member of the NF-κB family binds to slightly different consensus sequences found 
on gene promoters. For instance, the p50 member binds to GGGACTTTCC while the p52 
member prefers to bind to the sequence GGGATTCCCC (Fujita et al., 1992; Duckett et al., 
1993). Different compositions of the NF-κB heterocomplex will therefore result in alterations in 
promoter binding leading to a unique gene expression profile (Perkins, 1997). The vascular cell 
adhesion molecule-1 (VCAM-1) is regulated by specific NF-κB subunits (Shu et al., 1993). Shu 
et al determined that p65 alone or in a dimer with p50 can stimulate VCAM-1 expression.  In 
contrast, binding of the p52 subunit to the VCAM-1 promoter inhibited VCAM-1 expression and 
opposed p65 regulation of VCAM-1. 
 Simultaneous signaling transduction of NF-κB and other transcription factors are able to 
regulate NF-κB activity (Perkins, 1997). A promoter containing multiple consensus elements of 
various transcription factors may give rise to a competition for DNA binding.  Alternatively, the 
presence of DNA binding proteins may be necessary to allow for subsequent binding of 
transcription factors, as reported in IFNβ gene expression regulated by virus infection. NF-κB 
activation initiated by virus infection can upregulate IFNβ expression levels however 
TNFα−induced NF-κB activation does not effect IFNβ expression (Thanos and Maniatis, 1995).  
The IFNβ enhancer contains four elements available for various transcription factors. Only in the 
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presence of the enhancer proteins PRD, HMG I, and ATF2/c-Jun occupying the IFNβ enhancer 
can NF-κB bind to that promoter and initiate transcription.  The enhancer proteins, referred to as 
the enhancesome, are able to bend DNA in such a way to allow NF-κB to bind.  TNFα can 
activate NF-κB but does not regulate the proteins of the enhancesome therefore NF-κB does not 
effect IFNβ expression. Another example of heterologous signaling pathways affecting NF-κB 
gene regulation is shown in a study of IL-8 expression by DR3 and TNFR1 (Su et al., 2006). 
Although both receptors are able to upregulate IL-8 transcripts they require a different set of 
signaling pathways. The axis TAK1/ASK1-MKK4/MKK7-JNK2 is responsible for DR3 
expression of IL-8 whereas the axis ASK1-MKK4-JNK1/JNK2/p38MAPK is required for 
TNFR-1 expression of IL-8.  
 NF-κB translocation to the nucleus is another way to regulate NF-κB activity (Perkins, 
1997). The IκB family of proteins, responsible for sequestering NF-κB in the nucleus, are known 
to be activated and degraded in response to different stimuli.   For example IκBα can be targeted 
and degraded by TNFα, IL-1, LPS, and phorbol ester. However, LPS and IL-1 can only target 
IκBβ via an unknown mechanism (Thompson et al., 1995). Additionally, each IκB member can 
modulate NF-κB differently. IκBβ results in a longer sustained activation of NF-κB members as 
compared to that of IκBα.  Additionally, IκBβ competes with IκBα to bind to the NF-κB 
members (Perkins, 1997).   
 The differences of NF-κB suppression on the apoptotic pathway following VEGI 
stimulation of endothelial cells and TF-1 cells may be attributed to some the mechanisms stated 
above. For instance it is possible that each cell-type may contain a different distribution of 
factors of the NF-κB pathway, which can lead to a unique gene expression or possibly a 
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shorter/longer activation NF-κB.  If NF-κB is in fact not the primary mechanism determined to 
be involved in cell-type specificity for VEGI-mediated cell death we still would expect NF-κB to 
play an essential role. For instance, there may be an endothelial-specific receptor for VEGI that 
mediates apoptosis. However, it would still be necessary for NF-κB activation to have a tapered 
role on the apoptotic pathway and allow cell death to pursue. 
4.2  NF-κB INHIBITION LOOP DURING DR3 SIGNALING 
 In chapter 3 we show that DR3-depletion by siRNA can result in the enhanced NF-κB 
inducible activity. It is possible that DR3 during normal conditions is involved in deregulating 
the NF-κB pathway. The ability of DR3 to activate the NF-κB pathway as well as repress the 
NF-κB pathway would create a situation in which there is an inhibitory loop of NF-κB activation 
during DR3 signaling  (Figure 25). DR3 and other death receptors are normally thought of as 
having dual signaling arms with NF-κB representing the pro-survival arm and the caspase 
pathway representing pro-death arm. The pro-survival arm is able to regulate and suppress the 
pro-death arm as discussed above.  If DR3 activation resulted in an inhibitory loop to prevent 
NF-κB activation then pro-death would become unchecked and there would be increase in the 
apoptotic potential once DR3 is activated. If this inhibitory loop is specific for DR3 in 
endothelial cells and if it is determined that DR3 is the receptor for mediating VEGI-induced cell 
death, this may account for VEGI specificity towards endothelial cell death.  
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Figure 25. Potential NF-κB inhibitory loop in DR3 signaling.  DR3 is able to repress the 
NF-κB pathway by an unknown mechanisms (Dashed Blue Arrows). DR3 is also able to 
activate the NF-κB pathway (Black Arrow), resulting in a potential inhibitory loop on NF-
κB  activation following DR3 stimulation. This would suppress the pro-survival pathway 
and increase the apoptotic potential of DR3.  
4.2.1  Mechanisms that repress the NF-κB pathway 
The mechanism involved in DR3 repression of the NF-κB pathway is unknown.  However, it is 
presumed that DR3 is able to upregulate or downregulate factors via gene regulation, which in 
turn opposes activation of the NF-κB pathway. DR3 may directly regulate the expression of 
factors in the NF-κB pathway. We determined there was a 25% increase in p65 levels in ABAE 
cells following the depletion of DR3. This suggests that DR3 is involved in removing p65 from 
the cells during normal conditions.  Several studies reveal other mechanisms used to sequester 
NF-κB activity (Kucharczak et al., 2003; Scheidereit, 2006). Caspase-3 inhibits the NF-κB 
pathway be cleaving and deactivating proteins of the NF-κB pathway.  In particular p65, p50, 
and c-REL are known substrates for caspase-3 (Ravi et al., 1998). Thus, it is possible that DR3 
activation of caspase-3 can cleave and disable several NF-κB members in this fashion. Another 
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possible route to repress NF-kB activity is via the modulation of the phosphatases PP2A and 
PP2Cβ which are known to deactivate IKK (DiDonato et al., 1997). Deubiquitnaiton of UBlys63 
conjugated to the adaptor proteins TRAF or NEMO is another potent way to sequester NF-κB 
activity.  The Lys63-specific ubiquitin C-terminal deubiquitinase CYLD is able to bind IKKγ 
and TRAF and selectively degrades UBlys63 chains from IKKγ, TRAF2, TRAF6 or TRAF7, 
which disables these factors and thereby represses NF-κB activity (Brummelkamp et al., 2003; 
Kovalenko et al., 2003). These are possible directions that can be investigated in order to 
determine how DR3 is able to sequester NF-κB activity. A first approach to understanding DR3 
activity on NF-κB is to measure proteins levels of the canonical pathway, IKK1, IKK2, IKKγ, 
IκBα, p65 and p50. 
4.3  MULTIPLE RECEPTOR HYPOTHESIS FOR VEGI 
 We were unable to determine if DR3 is utilized by VEGI for mediating cell death. The 
pathways activated by VEGI however do resemble the typical activation of a death receptor. In 
figure 24 we depict a cell model for VEGI signaling derived from a single receptor however it is 
possible that these pathways are derived from two or more receptors.   Studies with TNFα 
interaction with TNFR-1 and TNFR-2 reveal how dual receptors can activate distinct and 
overlapping pathways. TNFR-1 is a typical death receptor capable of activating both pro-survival 
and apoptosis pathways. TNFR-2 does not contain a death domain and intracellular signaling is 
restricted to the activation of NF-κB and MAPK pathways. Additionally, TNFα activation of 
TNFR-1 and TNFR-2 result in opposing cellular responses in endothelial cells (Luo et al., 2006). 
In isolated murine endothelial cells TNFR-2 was shown to be responsible for the activation of 
NF-κB regulated genes, endothelial cell survival, and migration. In contrast TNFR-1 caused the 
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inhibition of migration and resulted in apoptosis.  
 So it is possible that pro-survival signaling can arise from one receptor and pro-death can 
arise from a second receptor.  In Chapter 3 we show that DR3-depleted cells continues to 
respond to VEGI-induced NF-κB activation. This suggests a second receptor for NF-κB 
activation. Since, DR3 is a death-domain containing receptor it would be expected to be involved 
the induction of apoptosis, that is, no other higher affinity death receptors can be activated by 
VEGI.   
 A recent study gives a clue to an unknown receptor for VEGI in endothelial cells.  An 
investigation of VEGI in chicken revealed VEGI mRNA transcripts in multiple tissues and 
organs (Takimoto et al., 2005). It was further determined that a recombinant VEGI preparation 
of the chicken homologue exhibited cytotoxicity to the mouse fibroblast L929 cells as wells as 
chicken fibroblasts.   Interestingly, the presence of TNFα is not detected in chicken and the 
authors hypothesized that VEGI may function as a substitute for TNFα in chickens. In fact the 
same group determined that the chicken homologues of VEGI and TNFR-2 can interact and 
mediate cell signaling (Takimoto et al., 2008). Thus, corroborating the hypothesis that VEGI is 
the alternate for TNFα in chicken.  Although there is an evolutionary distinction between 
chicken and human or bovine (the cell-typed used for our studies) these findings provide further 
evidence of VEGI using multiple receptors for cell signaling. Although it has been determined 
that human VEGI does not bind to human TNFR-2 as studied by a flow-cytometry based assay 
(Bossen et al., 2006). There are ligand/receptor interactions that require certain post-translational 
events  (Gutierrez et al., 2004) and a certain post-translational modification may be required for 
VEGI/TNFR-2 interaction that was duplicated in the previous reported flow cytometry assay.  A 
functional assay such a siRNA depletion of TNFR-2 may be useful approach to determine if 
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VEGI can utilize TNFR-2 for cell signaling, in particular NF-κB activation. 
4.4  DR3 REGULATION OF APOPTOSIS 
We show that once DR3 is depleted from endothelial cells the cells become protected from 
several apoptotic ligands.  These results suggest that DR3 may play a crucial role in the apoptotic 
pathway. It is unclear how DR3 is able to modulate the apoptotic pathway. In Figure 26 we 
propose two possible mechanisms of modulating the apoptotic pathway. One possibility is that 
DR3 is regulating a factor required for the apoptotic pathway, such that depletion of DR3 results 
in a gap in the pathway. Another possibility relates to the observation that DR3 in repressing the 
NF-κB pathway such that removal of DR3 increases NF-κB activity.  Increased NF-κB activity 
would increase production of anti-apoptotic proteins and be more effective at sequestering the 
apoptotic pathway and preventing cell death.   
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Figure 26. Two potential mechanisms that DR3 may regulate the apoptotic pathway. (A) 
DR3 may be involved in regulating a necessary factor utilized by the extrinsic apoptotic 
pathway. (B) Left, DR3 is able to repress the NF-κB pathway which would result in the 
diminished expression of anti-apoptotic factors. Right, when DR3 is depleted NF-κB 
activity becomes uninhibited leading to increased expression of anti-apoptotic proteins and 
enhanced survival. 
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 Regardless of the mechanism that DR3 is utilizing to regulate the apoptotic pathway our 
results suggest that DR3 is constitutively active under normal conditions. However, it is unclear 
what is activating DR3 during normal growth conditions. One such possibility is a serum factor, 
possibly VEGI, may be involved in stimulating DR3. So in the presence of normal growth media 
that factor is continuously stimulating DR3.  A second possibility is that E-Selectin may be 
activating DR3 during cell contacts. Colon cancer cells can communicate with endothelial cells 
via an interaction between DR3 and E-Selectin (Gout et al., 2006). This study investigated the 
cross-interaction with these two cell-surface proteins derived from different cell-types.  Since, E-
Selectin and DR3 are likely to be co-expressed in endothelial cells it is possible that these two 
receptors can interact during endothelial cell-cell contacts and possibly result in the constitutive 
activation of DR3. 
   
4.5  INFLAMMATION AND ENDOTHELIAL CELL ACTIVATION 
We  determined an anti-apoptotic role in NF-κB activation during VEGI stimulation of 
endothelial cells.  Not directly studied here but an important role of NF-κB activation in 
endothelial cells is its role in inflammation. Microvascular cells at the site of inflammation are 
known to directly regulate the inflammation process as well as communicate with inflammatory 
cells. During acute inflammation the quiescent endothelium undergoes a process of “endothelial 
cell activation” that initiates endothelial cells to help combat the inflammatory stimulus (Pober 
and Cotran, 1990). Endothelial cell activation in the absence of gene expression is known as type 
I activation, and endothelial cell activation that is dependent on gene expression is referred to as 
type II activation (Pober and Cotran, 1990).  Both type I and type II are marked by an increased 
in local blood flow, a localized leakage of plasma-protein-rich fluid, a localized recruitment and 
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activation of circulating leukocytes, and pain caused by mediators released by leuokocytes on C-
type sensory nerve fibres. (Pober and Sessa, 2007). Type I activation of endothelial cells is 
typically activated by G-protein-coupled receptor that leads to release of Ca2+ ions from the 
endoplasmic reticulum and the production of prostaglandin I2, a potent vasodilator (Egan and 
FitzGerald, 2006). Type I activation also involves inactivation MLC phosphatase, the 
phosphatase responsible for contracting actin filaments and involved in forming cell junctions. 
Inactivation of MLC leads to the opening of endothelial cell junctions thereby promoting 
vascular leakage of plasma proteins and neutrophil extravasation (Lorant et al., 1991; Teixeira 
et al., 1993).  
 Type I activation lasts for about 10-20 minutes and spontaneously resolves due to receptor 
desensitization.  Type II activation is a more lasting inflammatory response and persists as long 
as chemokines are still being produced and until the inflammatory stimulus is removed. The 
protypic members of type II activation are TNFα and IL-1 and their activation of the 
transcription factors NF-κB and AP-1 (Pober and Sessa, 2007). Type II activation can lead to 
induction of inflammatory molecules such as IL-8 production, which is responsible for 
neutrophil recruitment and upregulation of E-selectin. Type II activation can also lead to 
induction of the chemokine COX2, leading to increased blood flow similar to Type I activation 
(Smith et al., 2005). TNFα stimulation also involves actin reorganization and the opening 
intercellular junctions resulting in vascular leakage (Petrache et al., 2003). NF-κB negative 
feedback loops are involved in bringing type II activation to an end (Winsauer and de Martin, 
2007). 
    Since VEGI is an endothelial autocrine factor with similar signaling activities to TNFα we 
may expect VEGI to be involved in Type II activation of endothelial cells during acute 
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inflammation. We determined that VEGI can upregulate the chemokines IL-1β, IL-6 and IL-8 
via NF-κB thus exhibiting the potential of VEGI to direct endothelial cells to produce important 
cytokines involved in the inflammatory process. Further investigation would be of interest to 
determine if VEGI-induced NF-κB activation is playing a role in type II endothelial cell 
activation.  
4.6  NF-κB AS A TARGET FOR CANCER THERAPY 
 NF-κB is gaining attention as an important factor in cancer biology because of its involvement 
in tumor progression and therefore a potential target for anti-cancer drug development. 
Constitutive NF-κB activity is found in breast, prostate, colorectal, and ovarian cancers and 
certain forms of leukemia and lymphoma (Karin et al., 2002). The multifunction activities of NF-
κB may attribute to tumor progression as several steps.  The classical steps thought to be 
involved in cancer progression require the pre-neoplastic cell to become self-sufficient in growth 
signals, avoid both growth inhibitors and apoptosis, attain the ability to develop a limitless 
proliferation potential, increase mobility and metastasis potential, and modulate its nutrient 
supply by regulating angiogenesis (Hanahan and Weinberg, 2000). NF-κB can affect all of these 
processes by acting on the premalignant cell itself or by acting on inflammatory cells that are 
able to modulate the microenvironment (Karin and Greten, 2005).  One of the most prominent 
roles of NF-κB in tumor progression is the ability to regulate anti-apoptotic factors such as BCL-
2 a known oncogene (Danial and Korsmeyer, 2004).  In certain leukemias and lymphomas 
inhibiting NF-κB activation triggered apoptosis suggesting that the growth of these cells are 
dependent of NF-κB (Furman et al., 2000). NF-κB activation can also lead to the recruitment of 
several cells to the tumor microenvironment including macrophages, dendritic cells, neutrophils, 
mast cells, T cells and B cells (Greten et al., 2004, Pikarsky et al., 2004). These cells can produce 
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cytokines utilized by tumors for growth, production of angiogenic factors, and the production of 
proteases to degrade the extracellular matrix and support the growth of the tumor vasculature. 
NF-κB regulated genes IL-6 and IL-8 are known to be growth factors for premalignant cells and 
are involved in the stimulation of angiogenesis (Sparmann and Bar-Sagi, 2004). 
  Therefore there is close relationship between NF-κB activation, inflammation, and cancer 
progression. We propose that NF-κB inhibitors can be used in combination with VEGI as 
approach to cancer therapy. This approach would create a multi-targeting effect on the tumor. 
First NF-κB inhibition can work directly on the tumor to prevent activation of anti-apoptotic 
genes and proliferation. Additionally, NF-κB inhibition can prevent recruitment of inflammatory 
molecules that may be involved in the tumor progression.  Also VEGI combined with NF-κB 
inhibitors would create a potent apoptotic effect on the tumor vasculature.  
 It should be noted that it is possible that prolonged and substantial inhibition of NF-κB 
may not be practical when implemented as therapeutics because NF-κB is required for many 
fundamental processes (Nakanishi and Toi, 2005).  Thus, a more intermittent treatment of NF-κB 
inhibitors may be required.  An ideal approach to inhibiting the NF-κB pathway would be to 
target certain factors in the pathway that are only required for inducible NF-κB involved in the 
induction of anti-apoptotic genes and does not interfere with normal cellular functions. We 
discussed above several possible routes of stimulating and controlling NF-κB responsive genes. 
Elucidating the details of the VEGI-induced NF-κB pathway may provide for an ideal target.  
4.7  VEGI AND THE ANGIOGENIC BALANCE 
The role of VEGI as an anti-angiogenic factor is well established and shown in several in vitro 
and in vivo models. As a regulator of endothelial cell apoptosis it is possible that VEGI is 
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involved in the angiogenic balance and may oppose the actions of the pro-angiogenic factors 
such as VEGF and bFGF. One of the emerging pictures from our studies is the multiple level of 
balancing that may arise in the angiogenic balance and vascular homeostasis.   We established 
balancing role of NF-κB and apoptosis initiated by VEGI.  So VEGI may oppose pro-angiogenic 
factors but also activates pro-survival genes. These multiple levels of balance would contribute 
to the highly orchestrated process and fine-tuning of the angiogenic balance and vascular 
homeostasis.   
4.8  ENDOGENOUS INHIBITORS TO NORMALIZE THE VASCULATURE 
Endogenous inhibitors are thought to provide a promising approach to anti-angiogenic therapies 
because of their natural ability to inhibit endothelial cell growth. However, endogenous 
inhibitors role in normal physiology is thought to restore and maintain an angiogenic balance. 
Thus, endogenous inhibitors may contain checks so as not to overexert their inhibitory effect and 
avoid vascular damage. We determined VEGI utilizes NF-κB in order to control it’s apoptotic 
potential.  It is possible that VEGI and other endogenous inhibitors may not serve as ideal drugs 
that can completely deplete the tumor vasculature because of their partial survival activity. 
 Initially the use of anti-angiogenic drugs in clinical trials, only produced modest results and 
did not yield long-term survival benefits (Mayer, 2004). When the anti-angiogenic drug, 
bevacizumab, was used in combination with chemotherapy there was an unprecedented 5-month 
increase in colorectal cancer patients (Hurwitz et al., 2004). This treatment combination suggests 
that chemotherapy is able to inhibit growth of the tumor cells and bevacizumab is able to prevent 
angiogenesis.  However, this dual treatment is thought to be a paradox as anti-angiogenic therapy 
would diminish oxygen delivery, needed by the chemotherapeutics in order to be effective (Jain, 
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2005b). To account for this paradox it was hypothesized by Rakesh Jain that the bevacizumab 
may  “normalize” the tumor vasculature providing a more efficient delivery of drugs and oxygen 
to the tumor.  
 The tumor vasculature is highly tortuous and is structurally and functionally abnormal 
(Tian et al., 2002; Jain, 2005a).  These abnormalities in the tumor vasculature lead to a tumor 
microenvironment that is characterized by a high interstitial hypertension, hypoxia, and acidosis 
(Padera et al., 2004).  The tumor is able to survive under these conditions however these 
conditions create a barrier for drug delivery (Jain, 2005b). Chemotherapy and radiation therapy 
are oxygen-dependent and in hypoxic conditions will reduce the efficacy of these therapies. 
Also, hypoxia and low pH compromise the efficacy of the immune cells that infiltrate the tumor 
(Jain, 2005b). Another barrier in the drug delivery attributed to the tumor vasculature are the 
large holes found in the vasculature leading to vasculature leakiness.  This would result in an 
accumulation of the drug in certain parts of the tumor microenvironment and not all of the tumor 
regions would be accessible to the anti-cancer agents (Hobbs et al., 1998; Jain, 1999). Due to 
these barriers in the tumor vasculature Jain suggested if the tumor vasculature is normalized to 
be a more functional and structural conduit this will in turn lead to improved drug delivery to the 
tumor.  Additionally, the normalized vasculature may prevent malignant cells from entering the 
circulation and lower the metastatic potential of a primary tumor.   
 A slight variation of the normalization hypothesis to improve drug therapy is to  stabilize 
the vasculature to maintain cancer in a stable disease. Overexpression of the Angiopoetin-1 
results in the inhibition of tumor growth. Angiopoetin-1 increased pericyte coverage of the 
vasculature allowing for more functional blood vessels. It is hypothesized that this would revert 
the tumor state back to dormant state and prevents erratic angiogenesis that is required for tumor 
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progression.  
  Endogenous inhibitors of angiogenesis play a pivotal role in controlling the angiogenic 
balance but they become downregulated during tumor progression. Re-introduction of 
endogenous inhibitors in the tumor microenvironment may help to restore the angiogenic balance 
and maintain vascular homeostasis and direct the blood vessels to a more functional and 
quiescent state.  Thus it may be possible that endogenous inhibitors such as VEGI can improve 
drug delivery to the tumor or maintain cancer as a stable disease.   
4.9  FINAL WORD 
We focused on characterizing the molecular mechanisms of VEGI. We determined that NF-κB is 
a controlling factor in VEGI-mediated endothelial cell death and provide some potential new 
approaches to cancer therapy with the use of VEGI and NF-κB inhibitors.  We also investigated 
if DR3 is the receptor responsible for VEGI-mediated endothelial cell death. We were unable to 
make a ligand/receptor correlation between DR3 and VEGI.  However, we uncovered a novel 
role of DR3 and its needed presence for the induction of cell death by several apoptotic ligands, 
thereby establishing a unique role of DR3 in endothelial cell biology. These studies resulted in a 
clearer understanding of both VEGI and DR3 and it is the hope that these studies will make an 
impact cancer therapy.  
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